---

Question Bank Loaded

1. Automatically look up that question from your bank
2. Answer it at MD exam level using references from:
   • Miller's Anesthesia
   • Barash's Clinical Anesthesia
   • Morgan & Mikhail's Clinical Anesthesiology
   • Relevant international journals (where applicable)

---

Q175: Factors Controlling Coronary Blood Flow

---

Introduction

---

Coronary Perfusion Pressure (CPP)

CPP (LV) = Aortic Diastolic Pressure (AoDP) - LV End-Diastolic Pressure (LVEDP)

CPP (RV) = Aortic mean pressure - RV end-diastolic pressure

• Tachycardia shortens diastolic filling time and reduces LV perfusion time - this is the most important cause of perioperative ischemia
• Raised LVEDP (e.g., volume overload, poor compliance) reduces CPP
• Hypotension reduces AoDP and compromises perfusion

---

Autoregulation

• Autoregulation is effective between perfusion pressures of 50-120 mmHg
• Below 50 mmHg, flow becomes pressure-dependent (autoregulation is lost)
• Autoregulation of subendocardial flow is lost when perfusion pressure falls below 40 mmHg
• Beyond 120 mmHg, forced vasodilation occurs

---

Metabolic (Local) Regulation - The Primary Controller

Endothelin-1 (ET-1) is a potent vasoconstrictor produced by endothelium; under normal conditions its effect is counterbalanced by tonic NO release. Pathologic states (diabetes, hypertension, heart failure) tip the balance toward vasoconstriction.

---

Coronary Vascular Reserve

• Normal CVR = 3-5 times basal flow (500-600% of baseline for LV and RV)
• CVR is reduced by: epicardial stenosis, pressure-overload hypertrophy, microvascular dysfunction
• Stenosis of 50% luminal diameter = first impairment in reactive hyperemia
• Stenosis of ~90% = abolishes peak hyperemia = unstable angina threshold

---

Autonomic (Neural) Control

Sympathetic Nervous System

• Direct effects: Both α1 and β2 receptors present
  • α1 receptors: predominantly on larger epicardial vessels → vasoconstriction
  • β2 receptors: predominantly on smaller intramuscular/subendocardial vessels → vasodilation
• Indirect effects (dominant): Sympathetic stimulation ↑ HR and contractility → ↑ MVO2 → metabolic vasodilation overwhelms direct vasoconstriction
• Net effect: coronary blood flow increases with sympathetic stimulation due to dominant β2 + metabolic override
• Pathological exception: In some individuals, disproportionate α1 activation causes vasospastic ischemia (variant/Prinzmetal angina)

Parasympathetic Nervous System

• Vagal innervation of ventricular coronary vessels is sparse
• Acetylcholine has a direct, weak vasodilatory effect on coronary arteries
• Indirect effect: Vagal slowing of HR ↓ MVO2 → indirect vasoconstriction
• Net effect: minor and usually clinically insignificant

---

Humoral / Endocrine Factors

---

Physical / Mechanical Factors

Extravascular Compression

• LV flow is predominantly diastolic
• Tachycardia is particularly harmful - reduces diastolic time disproportionately

Heart Rate

• Increased HR = reduced diastolic perfusion time (supply ↓)
• Increased HR = increased MVO2 (demand ↑)
• This double jeopardy makes tachycardia the most dangerous factor in myocardial ischemia

Ventricular End-Diastolic Pressure

• Elevated LVEDP compresses subendocardial vessels and reduces CPP gradient
• Morgan & Mikhail specifically list LVEDP as both a supply factor (reducing perfusion) and a demand factor (increasing wall stress)

---

Myocardial Oxygen Supply-Demand Balance (Summary Table)

---

Oxygen Consumption Distribution

• Basal requirements: 20%
• Electrical activity: 1%
• Volume work: 15%
• Pressure work: 64%

---

Ischemia: Supply vs. Demand

---

Anaesthetic Implications

• Volatile agents: Most are coronary vasodilators; net effect on CBF is variable due to simultaneous reduction in MVO2 and blood pressure
• Spinal/epidural to T4: Decreases CBF in proportion to MAP reduction; can improve regional myocardial function in ischemic patients by reducing afterload and MVO2
• High thoracic epidural: Beneficial in ischemic heart disease - reduces sympathetic tone, wall stress, and MVO2
• Tachycardia prevention is the most important intraoperative goal - the single factor that simultaneously reduces supply and increases demand
• Vasopressors: Pure α-agonists (phenylephrine) increase AoDP (supply) but also increase afterload (demand); ephedrine increases HR (harmful); norepinephrine is generally preferred in hypotension with tachycardia

---

Key Points for MD Exam

1. Primary controller = metabolic regulation via adenosine, NO, KATP channels
2. Autoregulation range = 50-120 mmHg; subendocardial autoregulation lost at <40 mmHg
3. LV perfused in diastole only - tachycardia is the most dangerous hemodynamic change
4. CPP (LV) = AoDP - LVEDP; both ends of this equation must be optimized
5. Neural control is secondary and overridden by metabolic control within seconds
6. Coronary reserve = 3-5x basal flow; stenosis >50% begins to impair reactive hyperemia
7. Pressure work accounts for 64% of MVO2 - hypertension is the biggest demand driver
8. Endothelium is central - eNOS/NO, endothelin-1 balance; disrupted in atherosclerosis/diabetes

---

---

Q275: Management of Cardiac Arrest in Pregnancy

---

Introduction

---

Epidemiology

• Incidence: ~1 in 12,000 hospital deliveries
• Pregnant women are typically younger than the traditional cardiac arrest patient but outcomes are poor
• Maternal death from anesthesia has declined; leading anesthesia-related causes include failed intubation/induction problems (23%), respiratory failure (20%), and high spinal/epidural block (16%)

---

Causes of Cardiac Arrest in Pregnancy - The "ABCDEFGH" Mnemonic

---

Why Pregnancy Alters Resuscitation

Key Physiological Differences Relevant to CPR

---

Immediate Resuscitation Steps (AHA/ERC Algorithm for Pregnancy)

Step 1: Call for Help - Activate the Team

• Immediately call for: obstetric team, neonatal team, senior anaesthesiologist, surgical team capable of caesarean section
• Assign a team leader
• Do NOT delay CPR for team assembly
• Fetal monitoring should NOT be attempted during CPR - it distracts from maternal resuscitation

Step 2: Assess Gestational Age / Fundal Height

• If fundus at or below umbilicus (<20 weeks): Standard adult CPR, no modifications needed
• If fundus at or above umbilicus (≥20 weeks): Apply left uterine displacement (LUD) while performing CPR

Step 3: Left Uterine Displacement (LUD)

• A dedicated team member provides continuous manual LUD from the patient's right side, displacing the uterus to the patient's left
• One-handed or two-handed technique (one-handed preferred to keep team members free for other tasks)
• Tilting the patient 15-30° to the left on a wedge is an alternative but reduces CPR quality - manual LUD on a flat surface is preferred
• Chest compressions should still be in the standard supine position; compressions with patient tilted laterally are less effective

---

High-Quality CPR in Pregnancy

1. Aspiration risk (full stomach)
2. O2 consumption 30% above normal → rapid hypoxia
3. Reduced FRC → faster desaturation

---

Defibrillation and Medications

Defibrillation

• Indicated for shockable rhythms (VF/pulseless VT) at standard energy levels (biphasic: 120-200 J)
• Remove fetal electronic monitoring equipment before shock
• Defibrillation is safe - negligible energy reaches the fetus
• Automated external defibrillators (AEDs) are safe in pregnancy

Pharmacological Treatment - Considerations in Pregnancy

Special rule for eclampsia patients: If magnesium sulphate infusion is running at time of arrest - stop infusion immediately and administer calcium gluconate 10 mL of 10% solution IV as antidote to magnesium toxicity.

---

The Most Critical Intervention: Perimortem Caesarean Delivery (PMCD) / Resuscitative Hysterotomy

Rationale

• The gravid uterus causes significant aortocaval compression even with LUD
• Delivery of the fetus reduces oxygen demand of the uterus, relieves IVC compression, allows more effective chest compressions, and may be the only way to achieve ROSC
• Both maternal and fetal survival can be improved by timely delivery

The "5-Minute Rule"

If ROSC is not achieved within 4 minutes of initiation of resuscitation, perimortem caesarean delivery should be commenced immediately - targeting delivery within 5 minutes of cardiac arrest.

• Decision to proceed should be made at 4 minutes so delivery is completed by 5 minutes
• Do NOT wait for ROSC before deciding
• Do NOT transfer to the operating theatre - perform at the site of arrest (wastes critical time)
• CPR must be continued throughout the procedure and after delivery
• No general anaesthesia or spinal required - the patient is in cardiac arrest

Indications

• Gestational age ≥20 weeks (uterus at or above umbilicus)
• Failure to achieve ROSC with standard + modified CPR within 4 minutes
• Non-survivable maternal trauma (proceed immediately regardless of ROSC status)

Surgical Technique

• Vertical midline incision (fastest, no need for sterile technique in arrest)
• Classical uterine incision
• Rapid delivery of fetus and placenta
• Hand the neonate to the paediatric/neonatal team immediately

Expected Outcomes Post-PMCD

• Maternal: venous return improves → may precipitate ROSC
• Neonatal: neurologically intact survival possible if delivered <5 minutes from arrest
• Best documented neonatal outcomes when delivery occurs within 5 minutes; meaningful survival possible up to 15-20 minutes

---

Reversible Causes - The 4H + 4T + Obstetric Causes

---

Post-Cardiac Arrest Care (Post-ROSC)

1. Transfer to ICU for continued monitoring
2. Targeted Temperature Management (TTM): Therapeutic hypothermia (32-36°C) - traditionally controversial in pregnancy but now recommended if patient remains comatose post-ROSC; fetal bradycardia expected but tolerated
3. Coronary angiography/PCI if MI suspected (ST elevation or high suspicion)
4. Neurological monitoring: EEG for subclinical seizures, CT head if SAH/stroke suspected
5. Fetal monitoring: Continuous CTG monitoring post-ROSC if pregnancy ongoing
6. Treat underlying cause aggressively
7. Multidisciplinary team involvement: obstetrics, cardiology, ICU, neonatology

---

Algorithm Summary

MATERNAL CARDIAC ARREST
        ↓
Call for help: OBG + Neonatology + Anaesthesia + Surgery
        ↓
Start CPR immediately (100-120/min, ≥5 cm depth)
        ↓
Assess fundal height
   < Umbilicus → Standard CPR
   ≥ Umbilicus → Manual Left Uterine Displacement (LUD) + CPR
        ↓
Secure airway: RSI (bag-mask initially) → ETT
Establish IV/IO access × 2
12-lead ECG/rhythm analysis → Defibrillate if VF/pVT
        ↓
Treat reversible causes (4H + 4T + obstetric)
Stop magnesium infusion → give calcium if Mg toxicity
        ↓
At 4 minutes: NO ROSC achieved?
        ↓
PERIMORTEM CAESAREAN DELIVERY (PMCD)
Target delivery within 5 minutes of arrest
Do NOT move to OT - deliver at bedside
Continue CPR throughout and after delivery
        ↓
POST-ROSC CARE:
ICU + TTM + Treat cause + Fetal monitoring

---

Key Points for MD Exam

1. Two patients - but maternal resuscitation always takes priority; do not attempt fetal monitoring during CPR
2. LUD is mandatory when fundus is at or above umbilicus (≥20 weeks) - it restores up to 30-40% of venous return
3. Airway is higher priority than in general adult - O2 consumption is 30% above normal, FRC reduced; hypoxia develops rapidly
4. Perimortem caesarean delivery within 5 minutes is the most important intervention when ROSC is not achieved - it improves both maternal and neonatal outcomes
5. Do not move to OT - deliver at the site of arrest
6. Stop magnesium immediately if infusing; give calcium gluconate if toxicity suspected
7. Defibrillation at standard energy is safe; fetal monitors must be removed before shock
8. Amniotic fluid embolism is a unique and highly lethal cause - consider in sudden intrapartum collapse with DIC
9. Post-ROSC - TTM is considered even in pregnancy; coronary intervention as indicated
10. AHA 2025 guidelines (PMID: 41122893) endorse this approach - "resuscitative hysterotomy" is now the preferred term over "perimortem caesarean"

---

---

Q50: Safety Features of a Modern Anaesthesia Machine

---

Introduction

• ASTM International Standard F1850-00 (USA) - Standard Specifications for Anesthesia Workstations
• ISO 8835 (International)
• BS EN 740 (UK/Europe)

---

Classification of Safety Features

HIGH PRESSURE SYSTEM
├── Pipeline supply (DISS)
├── Cylinder supply (PISS)
└── Pressure regulators

INTERMEDIATE PRESSURE SYSTEM
├── Oxygen failure safety device
├── Hypoxic guard / O2:N2O ratio controller
├── Low O2 pressure alarm
└── Oxygen flush valve

LOW PRESSURE SYSTEM
├── Flow control (flowmeters)
├── Vaporizer interlocks
└── Common gas outlet

BREATHING CIRCUIT
├── APL valve / pressure relief
├── O2 concentration monitor
├── Capnograph
├── Airway pressure monitor
├── Volume monitor
└── Disconnect alarm

SCAVENGING SYSTEM
└── AGSS / Positive & negative pressure relief

---

I. High Pressure System Safety Features

1. Diameter Index Safety System (DISS) - Pipeline Inlets

• Purpose: Prevents incorrect connection of pipeline gas hoses to the anaesthesia machine
• Each medical gas (O2, N2O, Air, CO2) has a unique, gas-specific, threaded DISS connector
• The bore diameter of the body and the nipple of each connector are unique to each gas - physically impossible to misconnect
• A colour-coded hose connects the wall outlet to the machine via the DISS fitting
• A check valve is located downstream from each inlet - prevents reverse flow of gases from the machine back to the pipeline
• A pressure gauge at each inlet detects pipeline pressure and alerts to failure/depletion

2. Pin Index Safety System (PISS) - Cylinder (E-Cylinder) Connections

• Purpose: Prevents attachment of the wrong gas cylinder to a hanger yoke
• Two metal pins on the hanger yoke project into corresponding holes on the cylinder valve
• Each gas has a unique and specific pin hole arrangement (indexed positions 1-6)
• Physically impossible (under normal circumstances) to mount an incorrect cylinder
• Pin positions for common gases:
  • Oxygen: positions 2, 5
  • Nitrous oxide: positions 3, 5
  • Air: positions 1, 5
  • CO2: positions 1, 6
• The Bodok seal (rubber washer) between cylinder valve and hanger yoke ensures a gas-tight seal
• A check valve in each yoke prevents back-flow between cylinders when two cylinders of the same gas are mounted
• Limitation: PISS can be defeated if multiple washers are used; mixtures with >7% CO2 share the same pin arrangement as 100% CO2

3. Pressure Regulators

• Cylinder gas at high pressure (O2 cylinder: ~137 bar / 2000 psi) is reduced to a safe working pressure (~50 psi / 3.5 bar) by a two-stage regulator
• Pipeline supply enters at ~50-55 psi (4 bar); the regulator ensures the machine works at a consistent, safe pressure
• Prevents dangerously high pressures reaching the low-pressure circuit

---

II. Intermediate Pressure System Safety Features

4. Oxygen Failure Safety Device (Fail-Safe / Nitrous Oxide Cut-Off)

• Purpose: Prevents delivery of nitrous oxide (and other gases) when the oxygen supply fails
• Older machines: threshold shut-off valve - if O2 pressure drops below ~20 psig, a pneumatically operated valve cuts off N2O completely
• Modern machines: proportioning/balance regulator (Oxygen Failure Protection Device, OFPD) - proportionately reduces N2O pressure in response to falling O2 pressure (shuts off completely only below ~0.5 psig for N2O)
• In Dräger machines: called Oxygen Failure Protection Device (OFPD)
• In GE/Datex-Ohmeda machines: called Fail-Safe Valve
• Critical limitation: These devices protect only against O2 supply pressure failure. They do NOT protect against:
  • Crossed pipeline gases (N2O delivered in O2 pipeline)
  • Empty O2 cylinder with N2O pipeline in use
  • Dilution of O2 with a non-alarming inert gas
  • Low-pressure circuit leaks downstream

5. Minimum Oxygen/Nitrous Oxide Ratio Controller (Hypoxic Guard)

• Purpose: Ensures that the delivered gas mixture can never contain less than 21-25% oxygen regardless of flowmeter settings
• Mechanically or pneumatically links the N2O flow control valve to the O2 flow control valve
• If the operator attempts to set N2O to a level that would create a hypoxic mixture, the device automatically increases O2 flow (or limits N2O flow) to maintain minimum O2 concentration of at least 25% (some machines 21%)
• In Dräger machines: called Oxygen Ratio Monitor Controller (ORMC)
• In GE/Datex-Ohmeda machines: called Link-25 Proportioning System
• Limitation: Links only O2 and N2O - does not account for air, CO2, or other third gases added to the circuit

6. Low Oxygen Pressure Alarm

• Activates an audible alarm when the O2 supply pressure at the common inlet drops below a threshold (usually 20-30 psig)
• This is a continuously enabled, automatically activated alarm - it cannot be disabled
• Powered by a battery or pressurized gas reservoir so it functions even during power/gas failure

7. Oxygen Flush Valve

• Delivers 100% O2 at high flow (35-75 L/min) directly from the pipeline supply to the breathing circuit, bypassing flowmeters and vaporizers
• Critical safety point: The oxygen flush valve DOES NOT pass through the vaporizer - prevents accidental delivery of concentrated volatile agent
• Purpose: rapidly flush the breathing circuit with 100% O2
• Hazard: Can cause barotrauma if activated during inspiration (peak pressure can exceed 50 cmH2O); must not be activated during mechanical ventilation inspiration

---

III. Low Pressure System (Flow Control) Safety Features

8. Oxygen Flowmeter Positioned Furthest Downstream (to the Right)

• Oxygen enters the common manifold downstream to all other gases
• If a leak develops in an upstream (N2O or air) flowmeter, the leaked gas dissipates into the atmosphere before reaching the common outlet
• Downstream O2 position ensures delivered gas at the common gas outlet is O2-enriched even if upstream leaks occur
• By convention: O2 flowmeter is always the rightmost flowmeter in the bank

9. Oxygen Knob - Touch and Colour Coded

• The O2 flow control knob is fluted (octagonal), larger in size, and protrudes further than other knobs
• Touch-coded design allows identification in the dark
• Colour-coded: white (ISO/UK) or green (USA) consistent with cylinder/pipeline colour coding

10. Minimum Oxygen Flow

• Some machines deliver a minimum mandatory O2 flow (typically 50-100 mL/min) when turned on
• This ensures some O2 always enters the circuit even if the operator forgets to set O2 flow
• A minimum flow resistor prevents the O2 valve from completely shutting off

---

IV. Vaporizer Safety Features

11. Vaporizer Interlock Device (Selectatec System / Exclusion Device)

• Purpose: Prevents simultaneous use of more than one vaporizer
• If two or more vaporizers are mounted, the interlocking mechanism physically prevents more than one from being turned on at a time
• Dräger: interlock bar system; GE/Datex-Ohmeda: Selectatec manifold interlocking system
• Prevents accidental administration of a volatile anaesthetic cocktail

12. Keyed Filler Device (Agent-Specific Filling Port)

• Vaporizer filling ports are agent-specific via a keyed filling system
• Each volatile agent bottle has a unique adaptor that fits only the corresponding vaporizer
• Prevents filling a sevoflurane vaporizer with isoflurane or desflurane
• In Dräger machines: DIVA (Drug In Vaporizer Adaptor) system

13. Desflurane-Specific Heated Vaporizer Safety

• Desflurane's very high vapour pressure (669 mmHg at 20°C) and low boiling point (22.8°C) require a heated pressurised vaporizer (Tec 6 / D-Vapor)
• The vaporizer heats the agent to 39°C and delivers precise concentrations
• Safety: automatic shut-off if the heating element fails or if the vaporizer is tipped

---

V. Breathing Circuit Safety Features

14. Oxygen Concentration Monitor and Alarm

• An O2 analyser (paramagnetic or fuel cell/galvanic) is placed in the inspiratory limb of the breathing circuit
• Continuously measures inspired O2 concentration
• Alarm triggers if O2 falls below a preset threshold (typically 18-21%)
• This is an automatically enabled essential alarm - cannot be disabled

15. Capnography

• Continuous measurement of expired CO2 (ETCO2)
• Confirms tracheal intubation vs. oesophageal intubation
• Guides ventilation (prevention of hypo- or hyperventilation)
• Helps detect circuit disconnection, rebreathing, air embolism, malignant hyperthermia

16. Anaesthetic Gas Monitoring

• Measures inspired and expired concentrations of volatile anaesthetic agents
• Prevents anaesthetic overdose; assists in avoiding awareness

17. Airway Pressure Monitor and Alarms (Multiple Alarms)

• High pressure alarm: Activates above a set peak pressure (e.g., >40 cmH2O) - alerts to obstruction, bronchospasm, kinking
• Low pressure/disconnect alarm: Activates if circuit pressure remains below a threshold - indicates disconnection or major leak
• Sustained (plateau) pressure alarm: Alerts to prolonged elevated circuit pressure
• Negative pressure alarm: Alerts to negative PEEP or scavenging system dysfunction

18. Exhaled Volume (Spirometry) Monitor

• Measures exhaled tidal volume and minute volume
• Low volume alarm alerts to hypoventilation, disconnection, or circuit leak

19. Adjustable Pressure-Limiting (APL) Valve

• Operator-adjustable pressure relief valve in the breathing circuit
• Vents excess gas to the scavenging system at a set pressure (adjustable 0 to 70 cmH2O)
• Prevents barotrauma during manual/spontaneous ventilation
• Automatically excluded in most modern machines when the ventilator is activated (replaced by the ventilator's own spill/pop-off valve)

20. Inspiratory and Expiratory One-Way Valves (Circle System)

• Prevent rebreathing of expired gas without CO2 absorption
• Ensure unidirectional gas flow through the circle system
• Transparent domes allow visual inspection of valve leaflet movement

---

VI. Ventilator Safety Features

21. Ventilator Pressure Relief (Spill Valve)

• The ventilator bellows has an internal spill valve that opens during expiration to vent excess gas to the scavenging system
• Pneumatically closed during inspiration - ensures all delivered volume goes to the patient
• Prevents breath stacking and over-distension

22. Disconnect Alarm

• Detects loss of circuit integrity during mechanical ventilation
• If the breathing circuit disconnects, the pressure waveform flatlines → alarm triggers

---

VII. Scavenging System Safety Features

23. Anaesthetic Gas Scavenging System (AGSS)

• Collects and removes excess anaesthetic gases from the APL valve and ventilator spill valve
• Prevents operating room pollution and protects theatre staff from chronic anaesthetic exposure
• Safety: AGSS must have both positive pressure relief (prevents pressure build-up if scavenging blocked) and negative pressure relief (prevents excessive negative pressure being transmitted to the breathing circuit)

---

VIII. Electrical and Systems Safety Features

24. Automatically Enabled Essential Alarms

• Core alarms (O2 concentration, airway pressure, apnoea alarm) are automatically activated when the machine is turned on and cannot be disabled by the user
• Prevents use of the machine without essential monitoring in place

25. Battery Backup / Uninterruptible Power Supply (UPS)

• Modern anaesthesia workstations have battery backup to maintain monitoring and ventilation during power failure
• Enables continued patient ventilation during power outages

26. Electronic Integrated Self-Check (Automated Machine Checkout)

• On power-up, modern machines perform automated self-check of pneumatics, electronics, and breathing circuit integrity
• Alerts to any detected fault before case begins
• Supplements (but does not replace) the FDA/ASTM pre-use checklist

27. Integrated Data Systems

• Computerised processors integrate and monitor all components
• Automated anaesthesia record-keeping
• Networking to hospital information systems (HIS/EMR)
• Real-time trend monitoring and alarm integration

---

Summary Table of Key Safety Features

---

Pre-Use Safety Checklist (FDA/ASTM Recommended)

1. O2 cylinder pressure adequate (≥1000 psi)
2. Pipeline pressures (O2, N2O, Air) ~50 psig
3. Low O2 alarm functioning
4. O2 flush functioning
5. Flowmeters functioning; minimum O2 flow present
6. Vaporizers filled, tightened, and interlock working
7. Breathing circuit integrity (leak test <150 mL/min at 30 cmH2O)
8. Absorber CO2 canister fresh
9. All alarms active and set appropriately
10. Ventilator function checked
11. Scavenging system connected and functional
12. Emergency equipment available (laryngoscope, suction, drugs)

---

Key Points for MD Exam

1. DISS = pipeline safety; PISS = cylinder safety - both prevent gas misconnection
2. The fail-safe valve protects against O2 supply failure but NOT against crossed pipelines
3. The hypoxic guard (Link-25 / ORMC) links N2O flow to O2 flow - ensures minimum 25% O2
4. The O2 flowmeter is always rightmost/downstream - prevents hypoxia from upstream leaks
5. The O2 knob is fluted, larger, and protrudes further - tactile identification in the dark
6. O2 flush does NOT pass through vaporizer - delivers 100% O2 at 35-75 L/min
7. Vaporizer interlock prevents simultaneous use of two vaporizers
8. Automatically enabled alarms (O2 monitor, airway pressure, apnoea) cannot be turned off
9. AGSS must have bidirectional (positive AND negative) pressure relief
10. The preoperative automated + manual checkout is mandatory and is itself a safety feature

---

---

• Standard haemodynamic monitoring (arterial line, CVP, EtCO2, temperature)
• ICP monitoring (EVD gold standard; A/B/C waves; CPP targets)
• EEG and CBF thresholds for ischaemia
• Evoked Potentials (SSEP, MEP, BAER, VEP) - indications, warning criteria, anaesthetic considerations
• BIS/processed EEG
• SjvO2 and NIRS/rSO2 (cerebral oxygenation)
• TCD (vasospasm, emboli, CEA monitoring)
• PbtO2 (Licox system)

• Physiological basis of monitoring
• Sites (ulnar/adductor pollicis as gold standard; why NOT facial nerve)
• Types of monitors (MMG, AMG, EMG)
• All 6 modes of stimulation: Single twitch, TOF, Tetanic, PTC, DBS, 50 Hz burst - with detailed flowcharts and tables
• TOF count/ratio interpretation at each depth level
• DBS (Q29) - origin, rationale, comparison with TOF, clinical significance
• Anaesthetic importance - PRNB, reversal timing, extubation criteria, special populations
• Full intraoperative monitoring protocol flowchart

---

Q33: Train of Four (TOF) and Post-Tetanic Count (PTC)

---

Introduction

---

PART A: Train of Four (TOF)

Definition

• Stimulus parameters: square-wave, 200 µs duration, supramaximal current (40-60 mA)
• Applied every 10-15 seconds (to avoid post-tetanic facilitation artefact)
• Introduced by Ali and colleagues (1970)

The TOF Ratio

TOF ratio = T4/T1 (height of 4th twitch ÷ height of 1st twitch)

• Range: 0 (no T4 present) to 1.0 (full recovery)
• In the unblocked patient: T4/T1 = 1.0 (no fade)
• Fade = decreasing amplitude from T1 to T4 = hallmark of non-depolarising block

Why Fade Occurs in Non-Depolarising Block

• Non-depolarising NMBDs block post-junctional nicotinic receptors AND pre-junctional receptors
• Pre-junctional block ↓ ACh mobilisation during repetitive stimulation → successive ACh quanta get progressively smaller → declining twitch heights = fade
• Depolarising block (suxamethonium): No fade because pre-junctional receptors are NOT significantly blocked → all 4 twitches reduced equally (no fade)

Interpreting TOF Count and Ratio

TOF in Different Block Types

Advantages of TOF Over Single Twitch

Limitations of Qualitative (Clinical) TOF

• Visual/tactile detection of fade is only reliable when TOF ratio <0.4
• When TOF ratio is 0.4-0.9, fade cannot be detected manually → quantitative monitoring is essential
• Bijkerk et al. (Br J Anaesth, 2025): PRNB (TOF ratio <0.9) remains common even when TOF monitoring is performed - emphasising need for quantitative devices

---

PART B: Post-Tetanic Count (PTC)

Definition and Rationale

1. Assess whether block is truly intense (PTC = 0) or merely deep
2. Estimate time to recovery of T1 (to plan when to top up or when to wait for reversal)

Mechanism: Post-Tetanic Facilitation

• A tetanic stimulus (50 Hz × 5 sec) causes massive, sustained ACh release
• This depletes pre-synaptic ACh stores momentarily but also triggers a compensatory mobilisation of ACh from the reserve pool
• In the 3-second pause after tetanus, this enhanced ACh mobilisation persists
• When single-twitch stimuli are then given (1 Hz), the increased available ACh allows more post-synaptic receptors to be activated → transiently enhanced (facilitated) twitch responses
• This is post-tetanic facilitation (PTF)
• In profound block, PTF is what generates the PTC response; in fully blocked patients (zero reserve), no PTC twitches appear

Technique

Step 1: Deliver tetanic stimulus → 50 Hz for 5 seconds
Step 2: Wait exactly 3 seconds (pause)
Step 3: Apply single twitches at 1 Hz (every second)
Step 4: Count how many twitches appear (up to 20)
→ This count = POST-TETANIC COUNT (PTC)

Interpretation of PTC

Note: These times are approximations and vary with the NMBD used, patient factors, temperature, and drug interactions.

PTC and Reversal Agents

Important Rules for PTC

1. Wait ≥6 minutes after PTC before applying next TOF - post-tetanic facilitation distorts subsequent readings
2. PTC stimulation is not painful (performed under GA) but if patient is lightly anaesthetised, tetanic stimulation at 50 Hz can cause discomfort → avoid near awakening
3. PTC is only valid for non-depolarising block - not meaningful for suxamethonium phase I block
4. PTC overestimates block depth relative to laryngeal muscles (diaphragm and larynx recover faster than adductor pollicis)

---

Relationship Between TOF and PTC - A Unified Timeline

PROFOUND BLOCK ────────────────────────────────────── FULL RECOVERY
│                                                                    │
PTC = 0    PTC 1-5    PTC 6-10    TOF T1    TOF T1-T4    TOF ratio
                                 appears    all present    ≥ 0.90
│←────── Monitor with PTC ──────→│←──── Monitor with TOF ────────→│
                                             ↑
                                    Give reversal here
                                    (neostigmine or sugammadex)

---

Key Points for MD Exam - Q33

1. TOF = 4 stimuli at 2 Hz; ratio T4/T1; hallmark of non-depolarising block = fade
2. TOF ratio ≥0.9 required for safe extubation (quantitative monitor essential)
3. Fade visible tactilely only when TOF ratio <0.4; qualitative monitoring misses residual block between 0.4-0.9
4. PTC = tetanus (50 Hz × 5 sec) → 3 sec pause → 1 Hz single twitches; count the post-tetanic twitches
5. PTC used when TOF count = 0 (profound block)
6. PTC = 0 → truly intense block; PTC >0 → some recovery imminent; PTC ≥10 → T1 appearing soon
7. Wait 6 minutes after PTC before applying TOF again
8. Depolarising block: NO fade, no post-tetanic facilitation in phase I block

---

---

Q34: Bispectral Index (BIS) - Guidelines

---

Introduction

---

Physiological Basis: The EEG and Anaesthesia

• The brain generates spontaneous electrical activity detectable as the EEG
• Anaesthetic agents cause predictable, dose-dependent changes:
  • Light anaesthesia / sedation: ↑ beta (fast) activity (paradoxical activation)
  • Deeper sedation: ↑ alpha, ↓ beta
  • Surgical depth: ↑ delta/theta (slow waves), ↓ amplitude
  • Deep (isoelectric dose): burst suppression → flat (isoelectric) EEG

---

How BIS is Calculated

---

BIS Scale and Clinical Correlation

BIS SCALE
100 ─── Awake, responsive
 │
90  ─── Light sedation (responds to voice)
 │
80  ─── Moderate sedation (responds to stimulation)
 │
70  ─── Deep sedation / light anaesthesia
 │      (may respond to painful stimuli)
60  ─── ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ SURGICAL ANAESTHESIA TARGET
 │      UPPER LIMIT: BIS ~60
50  ─── TARGET RANGE 40-60 (surgical anaesthesia)
 │      Recall unlikely
40  ─── ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ LOWER LIMIT: BIS ~40
 │
30  ─── Deep anaesthesia / beginning of burst suppression
 │      (may reduce CMRO2)
20  ─── Heavy burst suppression
 │
 0  ─── Isoelectric (flat line EEG) / electrocerebral silence
         (deep barbiturate coma / profound hypothermia)

BIS Target Ranges by Clinical Scenario

---

BIS Monitor Setup

• A single disposable sensor electrode (BIS Quatro or Vista sensor) is applied to the forehead/temporal region
• Contains 4 electrodes: 3 EEG and 1 EMG (to detect high-frequency EMG artefact)
• Outputs:
  • BIS score (0-100)
  • SQI (Signal Quality Index): 0-100%; >50% needed for reliable reading
  • SR (Suppression Ratio): % of time EEG is suppressed (isoelectric); increases with deep anaesthesia
  • EMG bar: Shows frontalis muscle electromyographic activity that can falsely elevate BIS

---

Clinical Applications of BIS

1. Prevention of Intraoperative Awareness

• High-risk patients: Prior awareness, difficult/failed intubation, cardiac surgery, emergency C-section under GA, TIVA
• Maintain BIS 40-60 to minimise awareness risk
• B-Aware Trial (Myles et al., Lancet 2004): BIS-guided anaesthesia reduced awareness from 0.91% to 0.17% in high-risk patients
• B-Unaware Trial (Avidan et al., NEJM 2008): BIS NOT superior to ETAC (end-tidal anaesthetic concentration) guidance in general population - controversial
• BAG-RECALL Trial (Avidan et al., NEJM 2011): End-tidal volatile agent monitoring equivalent to BIS for awareness prevention
• Current consensus: BIS is useful particularly in TIVA (where ETAC cannot be measured) and high-risk patients

2. Titration of Anaesthetic Agents

• Prevents both over-anaesthesia (BIS <40 → adverse: prolonged recovery, haemodynamic depression) and under-anaesthesia (BIS >60 → awareness risk)
• Reduces drug consumption and speeds recovery
• Reduces PACU stay by ~10% (meta-analyses)

3. TIVA (Total Intravenous Anaesthesia)

• Most important application: No ETAC to guide depth
• BIS monitoring is strongly recommended (and by many considered mandatory) during TIVA with propofol/remifentanil
• Aim BIS 40-60; avoid exceeding BIS 60 during TIVA

4. Assessment of Burst Suppression for Cerebral Protection

• Post-cardiac arrest, status epilepticus, raised ICP
• BIS guides titration of propofol or thiopentone infusion to achieve burst suppression (BIS 15-25)
• SR (suppression ratio) >80% = deep burst suppression

5. Monitoring in ICU Sedation

• Titrate sedation in mechanically ventilated patients
• Target BIS 60-70 for appropriate sedation
• Helps reduce over-sedation (shorter ventilator weaning, less delirium)

6. Paediatric Anaesthesia

• BIS values differ in children vs. adults at equivalent clinical depths
• Neonates: BIS values are unreliable due to immature EEG
• Children >1 year: generally applicable; targets similar to adults

---

Factors Affecting BIS

Factors that DECREASE BIS (falsely deeper or genuinely deeper):

Factors that INCREASE BIS (falsely awake or artefact):

Critical point: A high BIS under NMBD may represent true awareness - the NMBD has abolished motor movement but the patient may still be conscious. This underscores why adequate hypnotic depth (BIS 40-60) must be confirmed when NMBDs are in use.

---

Limitations of BIS

1. Proprietary algorithm - exact weightings are not fully disclosed
2. Does NOT measure analgesia - a patient with BIS 45 may still mount a haemodynamic response to inadequate analgesia
3. Does NOT predict movement (immobility is primarily spinal cord-mediated)
4. Ketamine and N2O are poor predictors with BIS
5. EMG contamination is the most common clinical problem → falsely elevated BIS
6. Lag time: BIS has a time-averaging window (typically 10-30 seconds) → delayed response to rapid changes
7. Not validated for infants <1 year
8. Does not replace clinical assessment - must be interpreted in context

---

BIS and the ASA Guidelines

• The use of brain function monitoring (including BIS) is not routinely indicated for all patients undergoing general anaesthesia
• Should be considered in high-risk patients for awareness (TIVA, cardiac surgery, emergency C-section, previous awareness)
• TIVA without BIS is strongly discouraged by many institutional protocols

---

Key Points for MD Exam - Q34

1. BIS = processed, proprietary, dimensionless score derived from frontal EEG; range 0-100
2. Surgical anaesthesia target: BIS 40-60
3. Four sub-parameters: QUAZI, SynchFastSlow, Relative Beta Ratio, SEF95
4. Most important use: TIVA monitoring (no ETAC available)
5. EMG artefact is the most common source of falsely elevated BIS
6. Ketamine and N2O are not reliably reflected by BIS
7. BIS ≠ analgesic depth; ≠ immobility predictor
8. B-Aware trial: BIS reduced awareness in high-risk patients; B-Unaware/BAG-RECALL: Not superior to ETAC in general population
9. BIS 15-25 = burst suppression target for cerebral protection
10. Suppression Ratio (SR) = % of time EEG is isoelectric; rises with deep anaesthesia

---

---

Q35: Utility of Peripheral Nerve Stimulator for the Anaesthesiologist

---

Introduction

---

Technical Specifications of a PNS

Electrical Parameters

• Current output: Must be capable of delivering at least 50-80 mA (across 1000 Ω resistance) for supramaximal stimulation
• Pulse duration: 200 µs (square-wave, monophasic)
• Waveform: Square-wave (to prevent capacitive current effects)
• Supramaximal stimulation: 15-20% above the maximal stimulus needed - ensures all nerve fibres are activated regardless of changes in skin resistance intraoperatively

Electrode Placement

• Surface electrodes: Silver chloride ECG pads (preferred, non-invasive)
• Needle electrodes: Subcutaneous needles when surface electrodes fail (e.g., oedema, burns)
• Electrode placement: over the course of the nerve (NOT directly over muscle) to ensure nerve stimulation, not direct muscle stimulation

Monitoring Sites (Nerve-Muscle Units)

• Representative of peripheral muscles (which recovers LAST)
• Reproducible, quantifiable thumb movement
• Directly accessible with arm extended/supinated
• Correlates best with respiratory and pharyngeal muscle function

• Orbicularis oculi recovers BEFORE adductor pollicis
• Using facial nerve leads to underestimation of residual block → premature extubation → respiratory complications

---

Modes of Stimulation Available on a PNS

---

Utilities of the PNS: Clinical Applications

1. Confirming Onset of Block Before Intubation

• After NMBD injection, monitor TOF count
• Intubate when TOF count = 0 (single twitch also absent)
• Prevents incomplete relaxation → prevents vocal cord damage, bucking, awareness
• With rocuronium (1.2 mg/kg): TOF count 0 typically within 60-90 sec

2. Determining Depth of Block During Surgery

3. Guiding Top-Up Doses

• When TOF count rises to 2-3 (surgical relaxation becoming inadequate), a supplemental dose of NMBD is indicated
• Prevents patient movement at a critical surgical moment
• Avoids excessive accumulation from empirical re-dosing

4. Timing of Reversal Agent

Reversal Decision Tree
        ↓
Is TOF count = 0?
    ├── YES → Is PTC >0?
    │         ├── PTC = 0 → Too deep to reverse; wait or use Sugammadex 16 mg/kg
    │         └── PTC 1-2 → Sugammadex 16 mg/kg
    │
    └── NO → TOF count 1-3 → Sugammadex 4 mg/kg OR wait for TOF ≥2 for neostigmine
              TOF count = 4 → Quantify ratio:
                                TOF ratio ≥0.9 → Extubate
                                TOF ratio <0.9 → Sugammadex 2 mg/kg OR neostigmine 50 µg/kg

5. Confirming Adequate Recovery Before Extubation

• The MOST important safety application
• Safe extubation criterion: TOF ratio ≥0.90 (by quantitative monitor)
• Clinical signs alone are unreliable:
  • Head lift for 5 seconds: possible at TOF ratio 0.5-0.6
  • Tongue depressor test: possible at TOF ratio 0.7
  • Grip strength: possible at TOF ratio 0.6
  • None of these guarantee TOF ratio ≥0.9

6. Diagnosing and Managing Prolonged Neuromuscular Block (Phase II Block)

• Prolonged suxamethonium infusion → TOF begins to show fade (phase II block)
• This resembles non-depolarising block
• PNS identifies the transition and guides management (neostigmine may help in established phase II block; spontaneous recovery if mild)

7. Special Situations

Burns, Prolonged Immobility, Upper Motor Neurone Lesions

• Up-regulation of extra-junctional ACh receptors → resistance to non-depolarising NMBDs
• Higher doses needed; PNS guides titration to avoid underdosing (inadequate block) or overdosing

Myasthenia Gravis

• Marked hypersensitivity to non-depolarising NMBDs
• Pre-existing fade on baseline TOF
• PNS essential to detect even slight deepening of block and prevent respiratory crisis

Eaton-Lambert Myasthenic Syndrome

• Hypersensitivity to both depolarising and non-depolarising agents
• Unusual TOF pattern (pre-synaptic Ca²⁺ channel antibodies → incremental response to tetanic stimulation)

Neonates and Infants

• Immature NMJ → increased sensitivity to NMBDs
• Different TOF ratio norms; essential to monitor to prevent prolonged paralysis

Obese Patients

• Pharmacokinetic alterations; PNS guides accurate dosing

8. Monitoring During Prolonged ICU Paralysis

• Patients receiving continuous NMBD infusion for ICU ventilation (ARDS, status asthmaticus)
• PNS monitors depth: target 1-2 twitches on TOF (prevents both under- and over-paralysis)
• Prevents prolonged weakness (critical illness myopathy/polyneuropathy)

---

Qualitative vs. Quantitative PNS

---

Complications of PNS Use

• Skin irritation/abrasion at electrode site - most common
• Pain/discomfort (supramaximal stimulation) in lightly anaesthetised/awake patients - use submaximal current post-operatively with caution
• Direct muscle stimulation (if electrodes misplaced over muscle belly) → overestimates twitch count, underestimates block
• Electrical interference with other monitoring equipment (rare)
• Hematoma with needle electrodes

---

Summary of Utility: Why PNS is Indispensable

CLINICAL VALUE OF PERIPHERAL NERVE STIMULATOR
│
├── PRE-INTUBATION
│    └── Confirms complete block onset → safe intubation conditions
│
├── INTRAOPERATIVE
│    ├── Maintains optimal surgical relaxation (correct block depth)
│    ├── Guides supplemental dosing (prevents empirical over-dosing)
│    └── Diagnoses phase II block / unexpected block depth
│
├── REVERSAL
│    ├── Determines if reversal is appropriate (TOF ≥T2)
│    ├── Selects reversal agent (neostigmine vs. sugammadex)
│    └── Guides dose of reversal agent
│
├── EXTUBATION
│    └── Confirms TOF ratio ≥0.9 → the only objective criterion for safe extubation
│
├── PACU
│    └── Detects PRNB → immediate treatment before respiratory compromise
│
└── SPECIAL POPULATIONS
     └── Burns, MG, Eaton-Lambert, ICU, paediatrics, renal/hepatic failure

---

Key Points for MD Exam - Q35

1. PNS must be capable of ≥50 mA output for supramaximal stimulation
2. Gold standard site: Ulnar nerve → adductor pollicis; thumb must be free to move
3. Never use facial nerve to decide on extubation - it overestimates recovery
4. Five stimulation modes: single twitch, TOF, tetanic, PTC, DBS - each has distinct uses
5. IARS 2018: Quantitative PNS is mandatory whenever NMBDs are given
6. Safe extubation requires TOF ratio ≥0.9 by quantitative monitor - clinical signs are unreliable
7. PRNB (TOF ratio <0.9) in PACU occurs in 20-40% without monitoring → airway obstruction, hypoxia, aspiration
8. PNS guides reversal drug selection: PTC 0-2 → Sugammadex 16 mg/kg; TOF 2-4 → neostigmine or Sugammadex 2 mg/kg
9. In Myasthenia Gravis: baseline TOF fade is present; use PNS to avoid deepening
10. In ICU: target TOF 1-2 twitches during continuous NMBD infusion

---

---

Q68 & Q69: Halothane Hepatitis / Hepatotoxicity of Halothane

---

Introduction

---

Two Distinct Forms of Halothane Hepatotoxicity

Type 1 (Mild / Subclinical Hepatotoxicity)

Type 2 (Fulminant Halothane Hepatitis)

---

Pathophysiology: Immunological Mechanism

HALOTHANE
    ↓ CYP2E1 (Oxidative pathway - 20% of metabolism)
TRIFLUOROACETYL CHLORIDE (TFA-Cl)
[Highly reactive electrophile]
    ↓
Covalently binds hepatocyte surface proteins
    ↓
Trifluoroacetylated (TFA) PROTEIN ADDUCTS
[Act as neoantigens - foreign to immune system]
    ↓
On 1st exposure: Immune SENSITISATION
Anti-TFA antibodies form (detected in most halothane hepatitis patients)
    ↓
On RE-EXPOSURE:
Cytotoxic T-cell reaction + antibody-mediated
    ↓
MASSIVE HEPATIC NECROSIS (Halothane Hepatitis)

Key finding: In most patients who develop halothane hepatitis, antibodies against TFA-modified proteins are detectable in serum - confirming the immune mechanism.

---

Risk Factors for Halothane Hepatitis

---

Clinical Features of Halothane Hepatitis

Timeline

• Onset: 2-28 days after anaesthesia (typically 7-14 days after first exposure; sooner - 3-7 days - after re-exposure)
• This delayed onset distinguishes it from anaesthetic-related intraoperative hepatic ischaemia

Signs and Symptoms

• Fever (often the first sign; 75% of cases)
• Rash
• Arthralgia
• Eosinophilia

• Jaundice (progressively deepening)
• ↑↑ ALT, AST, Bilirubin, Alkaline phosphatase
• Coagulopathy (↓ PT, ↓ Factor V)
• Nausea, vomiting, anorexia, RUQ pain

• Hepatic encephalopathy
• Ascites, bleeding
• Renal failure (hepatorenal syndrome)
• Death in 50-75%

---

Diagnosis

• Clinical: Jaundice + fever + eosinophilia after halothane exposure (especially repeated)
• LFTs: Marked ↑ AST, ALT, bilirubin; ↑ PT; ↓ albumin
• Antibodies: Anti-TFA antibodies (serum) - positive in most cases
• Liver biopsy: Centrilobular (zone 3) hepatic necrosis (similar to toxic/ischaemic pattern)
• Exclusion: Rule out viral hepatitis (HBV, HCV, CMV, EBV), biliary disease, drug-induced hepatitis, ischaemia

---

Treatment

• No specific antidote
• Supportive:
  • Liver transplantation is the only definitive treatment for fulminant hepatic failure
  • Correction of coagulopathy (FFP, vitamin K)
  • Lactulose, rifaximin for hepatic encephalopathy
  • Monitor electrolytes, renal function, blood glucose

---

Cross-Reactivity with Other Halogenated Agents

Why sevoflurane is safer: Sevoflurane is oxidised at the fluoromethoxy C-H bond → forms hexafluoroisopropanol (HFIP) and inorganic fluoride. HFIP is relatively stable and does NOT covalently modify hepatic proteins → no TFA neoantigen formation.

---

Prevention

1. Avoid halothane (now withdrawn from adult use in most countries)
2. Do not re-administer halothane within 3 months (minimum 6 months ideal) if given once before
3. Avoid in patients with unexplained jaundice or fever after previous halothane anaesthesia
4. Use modern agents (sevoflurane, desflurane) - extremely low hepatotoxicity risk
5. If cross-reactivity suspected: avoid all halogenated agents → use TIVA (propofol)

---

Key Points for MD Exam - Q68/69

1. Two forms: Type 1 (mild, 20%, reductive CYP2A6 pathway) and Type 2 (fulminant halothane hepatitis, 1:5000-35,000, oxidative CYP2E1 pathway)
2. Mechanism: CYP2E1 → trifluoroacetyl chloride → TFA-protein adducts → immune sensitisation → T-cell cytotoxicity → massive hepatic necrosis
3. Anti-TFA antibodies are the diagnostic hallmark
4. Risk factors: re-exposure (especially <6 weeks), obesity, female sex, middle age, enzyme inducers
5. Clinical: fever + jaundice + eosinophilia after halothane, 7-14 days post-operatively
6. Mortality 50-75% in fulminant form; liver transplant is the only cure
7. Sevoflurane does NOT form TFA adducts → much safer profile
8. All halogenated agents (except sevoflurane) form identical TFA adducts → cross-reactivity exists
9. Children have 16-40x lower incidence than adults (reason unknown)
10. Halothane is now withdrawn from adult use in most developed countries

---

---

Q70: Diffusion Hypoxia

---

Definition

---

Mechanism

N2O DISCONTINUED
        ↓
Large volumes of dissolved N2O diffuse FROM BLOOD → INTO ALVEOLI
(N2O is 35x more soluble in blood than nitrogen)
        ↓
N2O floods the alveolar space rapidly (up to 1-1.5 L/min initially)
        ↓
TWO SIMULTANEOUS EFFECTS:

1. DILUTION OF ALVEOLAR OXYGEN
   Alveolar O2 is diluted by incoming N2O
   → PaO2 falls transiently
   → HYPOXIA if patient breathes room air

2. DILUTION OF ALVEOLAR CO2
   Alveolar CO2 is also diluted by incoming N2O
   → PETCO2 falls transiently
   → ↓ Respiratory drive (CO2-mediated)
   → Hypoventilation worsens hypoxia

---

Time Course

• Begins: Immediately after N2O is discontinued
• Peaks: First 5-10 minutes of recovery
• Duration: 5-15 minutes (until blood N2O is fully washed out)
• Greatest risk: In recovery room when patient is breathing room air

---

Relationship to the Concentration and Second Gas Effect (Reverse Process)

---

Predisposing Factors

---

Clinical Significance

• Magnitude: PaO2 can fall by 10-15 mmHg in the early recovery period
• Transient and self-limiting BUT in elderly, obese, or patients with cardiorespiratory disease, even brief hypoxia is dangerous
• Contributes to postoperative hypoxia alongside residual anaesthetic agents, NMBD, opioids

---

Prevention (Simple and Effective)

Give 100% oxygen for 3-5 minutes at the end of N2O anaesthesia before extubating and before transfer to PACU.

1. Washes out N2O from the alveoli using high-flow O2
2. Creates an O2 reservoir in the alveoli and FRC to buffer any subsequent dilution
3. Is universally recommended and easily implemented

---

Key Points for MD Exam - Q70

1. Diffusion hypoxia = Fink effect = transient ↓ PaO2 when N2O is stopped at end of anaesthesia
2. Cause: Rapid outward diffusion of N2O from blood → alveoli → dilutes alveolar O2 and CO2
3. Peaks at 5-10 minutes of recovery; lasts 5-15 minutes
4. Also causes transient ↓ PaCO2 → ↓ respiratory drive → hypoventilation → compounds hypoxia
5. Greatest risk with high N2O concentrations and long cases
6. Prevention: 100% O2 for 3-5 minutes at end of N2O anaesthesia (pre-oxygenation/post-oxygenation)
7. Reverse of the second gas effect seen at induction

---

---

Q71 & Q72: Uptake and Distribution of Inhalational Agents + Properties of Xenon + Short Note on Sevoflurane

---

Introduction

---

The FA/FI Ratio: The Central Concept

FA = Alveolar concentration FI = Inspired concentration FA/FI ratio rises towards 1.0 as anaesthesia deepens

• The rate of rise of FA/FI determines the speed of induction
• A fast rise of FA/FI = rapid induction (e.g., N2O, desflurane)
• A slow rise of FA/FI = slow induction (e.g., halothane, ether)

---

Factors Determining Uptake and Distribution

1. Inspired Concentration (FI) - Controlled by Anaesthesiologist

• Higher FI → faster rise of FA → faster induction
• Concentration effect: With highly soluble agents given at high concentrations (especially N2O at ≥50%), the rapid alveolar uptake of gas creates a "vacuum" in the alveolus → tracheal inflow accelerates → remaining gases concentrate → FA rises faster than predicted
• Second gas effect: Concentration effect on N2O accelerates uptake of a simultaneously administered volatile agent (e.g., sevoflurane), speeding its induction

2. Alveolar Ventilation (VA)

• ↑ Ventilation → ↑ rate of rise of FA/FI → faster induction
• This is particularly important for highly soluble agents (e.g., halothane, ether)
• Less important for poorly soluble agents (N2O, desflurane) because blood/gas partition coefficient is the limiting factor
• Controlled ventilation speeds induction
• Hyperventilation (e.g., in anxious, crying child) speeds inhalational induction
• Respiratory depression slows induction (self-limiting; as FA ↓, effect ↓ → ventilation improves)

3. Blood-Gas Partition Coefficient (λ) - The Most Important Factor

λ (blood/gas) = concentration of agent in blood / concentration in alveolar gas at equilibrium

• Represents solubility of agent in blood
• High λ = highly soluble = blood acts as a "sponge" absorbing agent = FA rises SLOWLY = slow induction
• Low λ = poorly soluble = blood absorbs little = FA rises RAPIDLY = fast induction

4. Cardiac Output (Q)

• ↑ Cardiac output → ↑ uptake of agent from alveoli → FA rises MORE SLOWLY → slower induction
• This seems paradoxical but: high CO removes agent from alveoli faster than it can be replenished by ventilation → alveolar concentration (FA) is kept low → slow equilibration
• ↓ Cardiac output (e.g., shock, cardiac failure): Less uptake from alveolus → FA rises RAPIDLY → faster induction AND risk of overdose
• Critical: In shock states, induction dose of volatile agent should be significantly reduced

Note: Cardiac output effect is greatest for highly soluble agents; less important for poorly soluble agents (little uptake regardless of CO)

5. Alveolar-to-Venous Partial Pressure Difference (PA - PV)

• Represents the concentration gradient driving uptake of agent from alveolus into blood
• At the START of induction: large gradient (PV = 0, PA rising) → maximum uptake
• As anaesthesia proceeds: tissues equilibrate → PV rises → gradient narrows → uptake slows → FA rises faster
• This is why speed of induction slows over time even with constant FI

6. Tissue Partition Coefficients and Tissue Groups

• VRG equilibrates first → accounts for induction and initial anaesthesia
• Muscle group acts as a reservoir - takes up agent over 30-60 min → slows FA rise with time
• Fat group accumulates agent very slowly but retains it - contributes to prolonged recovery after long cases, especially with soluble agents

7. Agent Physical Properties

• Desflurane: 669 mmHg (very high → needs special heated vaporiser)
• Sevoflurane: 160 mmHg
• Isoflurane: 238 mmHg

---

Wash-Out and Emergence

• Mirror image of wash-in
• Low solubility → fast emergence (desflurane, sevoflurane > isoflurane > halothane)
• Fat stores act as a depot - release agent slowly during emergence → prolonged recovery with soluble agents after long cases
• Metabolism contributes minimally to emergence for modern agents (except halothane where metabolism removes ~20%)

---

Summary: Factors Affecting FA/FI Rise

FASTER FA/FI RISE                    SLOWER FA/FI RISE
(Faster induction)                   (Slower induction)
─────────────────                    ─────────────────
↑ Inspired concentration             ↓ Inspired concentration
↑ Alveolar ventilation               ↓ Alveolar ventilation (hypoventilation)
LOW blood/gas partition coeff        HIGH blood/gas partition coeff
↓ Cardiac output                     ↑ Cardiac output
Small tissue compartments            Large, well-perfused tissue beds
(↑ PV quickly → ↓ gradient)

---

PART B: Properties of Xenon

Physical Properties

Why Xenon is "Ideal"

• Stable: No chemical reactions; no degradation in soda lime or carbon dioxide absorbers
• Non-biotransformable: Not metabolised at all → no toxic metabolites → no organ toxicity
• Nontoxic: No liver, kidney, or bone marrow toxicity
• Nonflammable
• Nonirritant
• Lowest blood/gas partition coefficient (0.115): Faster induction and recovery than any other inhalational agent
• Haemodynamically stable: Sympathomimetic effect → maintains BP and reduces HR (unlike volatile agents which depress CVS)
• Analgesic properties (NMDA receptor antagonism, similar to ketamine)

Mechanism of Action

• Primary: NMDA receptor antagonism (N-methyl-D-aspartate) in CNS
• Also: two-pore domain K+ channel activation, voltage-gated Ca²⁺ channel inhibition
• Does NOT interact with GABA receptors (unlike volatile agents)

Clinical Properties

Disadvantages of Xenon

1. Prohibitively expensive - occurs naturally in atmosphere at only 0.086 ppm; extraction is costly
2. Requires closed-circuit delivery system (to recapture and reuse - not scavenged)
3. Cannot be used in patients with bowel obstruction, pneumothorax (expands gas-filled spaces like N2O)
4. High MAC (63-71%) → limited additional O2 can be given (max ~30% O2 with 70% Xe)
5. Currently no commercially widely available delivery systems in most countries
6. PONV risk higher than volatile agents

---

PART C: Short Note on Sevoflurane (Q72)

Physical Properties

Pharmacological Properties

• ↓ CMRO2 in proportion to depth
• ↓ CBF at higher concentrations; vasodilation at >1 MAC
• ↑ ICP (dose-dependent); use with caution in raised ICP
• Epileptiform EEG changes with sevoflurane (especially in children at high concentrations; clinical significance debated)
• Smooth induction - non-pungent, sweet odour → ideal for gas induction especially in paediatrics

• ↓ SVR, ↓ MAP (dose-dependent)
• Heart rate relatively unchanged (unlike desflurane which causes tachycardia)
• Cardioprotective: Preconditioning effect - reduces ischaemia-reperfusion injury (important in cardiac surgery)
• Does NOT sensitise myocardium to catecholamines (unlike halothane)
• Safe in patients with CAD

• Bronchodilator - ideal in asthma patients
• ↓ Tidal volume, ↑ respiratory rate (net: ↓ MV)
• ↓ Hypoxic pulmonary vasoconstriction (HPV) at >1 MAC

• Potentiates NMBDs (~25-30% dose reduction vs. TIVA)

• Does NOT form TFA adducts → extremely rare hepatitis
• Cases reported but WITHOUT proven immune mechanism

• Compound A: Sevoflurane reacts with dry soda lime (especially at high temperatures) → forms fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (Compound A)
• Compound A is nephrotoxic in rats at high concentrations
• In humans: At clinical concentrations, Compound A does NOT cause significant renal injury
• Recommendation: Flow rates >2 L/min to reduce Compound A accumulation (particularly with Baralyme); avoid very low flow <0.5 L/min with old-generation soda lime
• Inorganic fluoride: ~3-5% of sevoflurane is metabolised → releases inorganic fluoride (F⁻), peak serum F⁻ ~20 µmol/L (below nephrotoxic threshold of 50 µmol/L); clinically safe

• Non-pungent (fruity/sweet smell): Best agent for gas/mask induction (especially in children, needle-phobic adults)
• Low blood/gas coefficient: Fast induction AND fast recovery
• No airway irritation → no breath-holding, coughing, laryngospasm on induction

---

Key Points for MD Exam - Q71/72

1. FA/FI ratio is the core pharmacokinetic concept; determined by ventilation, blood solubility, cardiac output, and inspired concentration
2. Blood/gas partition coefficient is the single most important determinant of speed of induction and emergence
3. ↑ CO → slower induction; ↓ CO → faster induction (beware overdose in shock)
4. Tissue groups: VRG equilibrates in minutes; muscle in 30-60 min; fat in hours-days
5. Second gas effect: N2O at high concentration accelerates uptake of co-administered volatile agent
6. Xenon: MAC 63%; blood/gas λ = 0.115 (fastest induction/emergence); NMDA antagonist; ideal properties but prohibitively expensive
7. Sevoflurane: Blood/gas λ = 0.65; MAC 2%; non-pungent → best agent for gas induction; Compound A is nephrotoxic in rats but not clinically significant in humans; no TFA adducts → safe hepatic profile
8. Sevoflurane bronchodilates → drug of choice in asthmatic patients
9. Sevoflurane provides cardiac preconditioning → preferred in cardiac surgery

---

---

Q73: Environment and Inhalational Anaesthetics

---

Introduction

1. The anaesthesia scavenging system (which vents to atmosphere)
2. Exhaled gases from patients in the PACU/recovery room
3. Leaks from anaesthesia machines and circuits

• Global warming (greenhouse gas effect)
• Stratospheric ozone depletion

---

I. Global Warming Potential (GWP)

Definition

• GWP = the ability of a greenhouse gas to trap heat in the atmosphere relative to CO2 over a specified time horizon (usually 100 years = GWP100)
• GWP of CO2 = 1 (reference standard)

Mechanism

• Volatile anaesthetic molecules contain C-F bonds (carbon-fluorine)
• C-F bonds absorb infrared radiation (heat) reflected from Earth's surface
• This warms the atmosphere = greenhouse effect
• Long atmospheric lifetime compounds the effect

GWP and Atmospheric Lifetime of Anaesthetic Gases

Desflurane is 2,540× more potent as a greenhouse gas than CO2 - using 1 mL of liquid desflurane is approximately equivalent to driving a car 20-60 km in terms of CO2-equivalent emissions.

Nitrous oxide has a GWP of 265 but an atmospheric lifetime of 114 years, making it the most persistent anaesthetic greenhouse gas.

---

II. Stratospheric Ozone Depletion

Mechanism

• Nitrous oxide (N2O) is the primary anaesthetic contributing to stratospheric ozone depletion
• N2O is currently the largest active ozone-depleting substance emitted by human activities (Ravishankara et al., Science 2009)
• N2O rises to the stratosphere → broken down by UV radiation → produces nitric oxide (NO) radicals
• NO radicals catalytically destroy ozone (O3): NO + O3 → NO2 + O2
• Volatile halogenated agents also contribute to some degree (via F and Cl radicals) but much less than N2O for ozone

N2O and Ozone

• Healthcare sector contributes ~3% of global N2O emissions
• Desflurane, isoflurane, and sevoflurane have very minor ozone depletion potential compared to N2O

---

III. Operating Room Pollution (Occupational Exposure)

Sources of Pollution

• Poorly fitting face masks during inhalational induction
• Poorly fitting LMA or ETT connections
• High-flow techniques with no scavenging
• Disconnection from scavenging
• Open vaporisers

Health Effects on Theatre Staff (Chronic Low-Level Exposure)

Recommended Maximum Exposure Limits (UK COSHH/NIOSH)

• N2O: <25 ppm (NIOSH); <100 ppm (UK) over 8-hour TWA
• Halothane: <5 ppm
• Other volatile agents: Various standards exist

---

IV. Mitigation Strategies

A. Scavenging (AGSS - Anaesthetic Gas Scavenging System)

• Most effective single measure
• Collects exhaled gases from APL valve and ventilator → vents to atmosphere away from OR
• Must have positive AND negative pressure relief valves
• Active or passive scavenging systems
• Reduces theatre pollution by 90-95%

B. Low-Flow Anaesthesia

• Reduces the volume of volatile agent consumed per case
• Less agent vented to atmosphere via scavenging
• Examples:
  • Minimal flow: 0.5 L/min fresh gas flow
  • Low flow: 0.5-1 L/min
  • Requires closed/semi-closed circle system, CO2 absorber
• Can reduce desflurane emissions by up to 80% compared to high-flow techniques

C. Agent Selection - Choosing Greener Agents

ENVIRONMENTAL PRIORITY ORDER (most to least green):

XENON → Sevoflurane → Isoflurane → N2O → Desflurane
(GWP=0)    (GWP=130)     (GWP=510)   (GWP=265)  (GWP=2540)

• Avoid desflurane for routine surgery (many institutions have now banned it)
• Prefer sevoflurane or propofol (TIVA)
• Limit or eliminate N2O - significant ozone impact due to very long atmospheric lifetime
• TIVA with propofol has minimal environmental footprint (metabolised and eliminated in urine)

D. Regional and Neuraxial Anaesthesia

• Eliminates all volatile agents and N2O
• Environmentally the best anaesthetic option where clinically appropriate

E. Desflurane Phase-Out

• Multiple national anaesthesia societies (UK, France, Germany, Canada) have published statements or guidelines to phase out desflurane by 2025-2030
• The AAGBI (UK) and SFAR (France) have recommended desflurane should no longer be used for routine surgery

F. Capture and Destruction Technologies

• Zeolite-based capture: Adsorbs volatile agents from exhaled gas before scavenging to atmosphere; allows quantification and disposal
• CONtRol (volatile agent capture) systems currently being developed
• Incineration of waste gases at high temperature

---

V. Regulatory and Professional Context

---

Summary Table

---

Key Points for MD Exam - Q73

1. Desflurane has the highest GWP (2,540) → worst greenhouse gas in anaesthesia; being phased out globally
2. N2O has GWP 265 AND atmospheric lifetime of 114 years AND is the largest active ozone-depleting substance - doubly harmful
3. Xenon has GWP = 0 → perfectly green but impractical due to cost
4. TIVA (propofol) and regional anaesthesia have minimal environmental footprint
5. AGSS (scavenging) is the most important single measure to reduce theatre pollution
6. Low-flow anaesthesia significantly reduces volatile agent consumption and atmospheric emissions
7. N2O → chronic exposure → B12 inactivation → bone marrow suppression, subacute combined degeneration, reproductive effects
8. Professional societies worldwide recommend phasing out desflurane for routine surgery
9. GWP = heat-trapping ability relative to CO2 over 100 years (CO2 = 1)
10. Nielsen & Andersen (Anaesthesia 2024 [PMID: 38206102]) - current definitive atmospheric science review of volatile agents

---

Q185 & Q186: Traumatic Brain Injury (TBI) — Updates and Anaesthetic Concerns

---

Definition and Classification

Classification by GCS (Glasgow Coma Scale)

The motor component of GCS is the single strongest predictor of outcome following TBI.

Classification by Pathology

---

Pathophysiology

Primary Injury Mechanisms

• Focal: Contusion, laceration, epidural/subdural/intracerebral haematoma
• Diffuse: Diffuse axonal injury (DAI) - shearing of axons at grey-white junction by acceleration-deceleration
• Subarachnoid haemorrhage, intraventricular haemorrhage

Secondary Injury - The Therapeutic Target

PRIMARY BRAIN INJURY (irreversible)
         ↓
Triggers cascade:
  - Cytotoxic oedema (Na+/K+ pump failure → cellular swelling)
  - Vasogenic oedema (BBB disruption → protein leak → interstitial swelling)
  - ↑ ICP
  - ↓ CPP = MAP - ICP
  - Ischaemia → excitotoxicity (glutamate release → NMDA receptor activation → Ca²⁺ influx → cell death)
  - Mitochondrial dysfunction → ATP depletion
  - Inflammation → further oedema
  - Herniation if untreated
         ↓
SECONDARY BRAIN DEATH (preventable)

• Hypotension (SBP <90 mmHg) - single most important preventable secondary insult
• Hypoxia (SpO2 <90%, PaO2 <60 mmHg)
• Hyperthermia
• Hypoglycaemia / hyperglycaemia
• Hypercarbia / hypocarbia
• Seizures
• Coagulopathy (TBI releases tissue factor → DIC)

---

Glasgow Coma Scale

---

Initial Assessment and Resuscitation (ATLS/BTF Guidelines)

Primary Survey: ABCDE

• A - Airway: Protect with cervical spine immobilisation; intubate if GCS ≤8
• B - Breathing: Maintain SpO2 ≥98%; avoid hypoxia; target PaO2 >80 mmHg; avoid hyperventilation (↓ CBF)
• C - Circulation: Target SBP ≥90 mmHg (adults); ≥100 mmHg in elderly; MAP ≥80 mmHg; avoid hypotension aggressively
• D - Disability: GCS, pupils (blown pupil = transtentorial herniation → emergency); blood glucose
• E - Exposure: Head-to-toe examination; CT head/neck

Imaging

• CT head (non-contrast): Imaging of choice; immediate if GCS <14 or focal neurological deficit
• CT spine: C-spine immobilisation until cleared
• MRI: Better for diffuse axonal injury, brainstem injury, subacute haematoma; not practical acutely

---

Brain Trauma Foundation (BTF) 4th Edition Guidelines — Key Targets

---

ICP Management — Tiered Approach

TIER 0 (Basic — ALL patients)
  - Head elevation 30° (neutral position, no neck compression)
  - Sedation and analgesia (propofol/midazolam + morphine/fentanyl)
  - Avoid hyperthermia, hypoxia, hypotension, hypercarbia
  - Prevent seizures (prophylactic levetiracetam 7 days for severe TBI)
  - Normoglycaemia
         ↓ ICP still >20 mmHg

TIER 1
  - CSF drainage via EVD (External Ventricular Drain)
  - Optimise analgesia/sedation
  - Mannitol 0.25–1 g/kg IV bolus OR Hypertonic saline (3-7.5%)
  - Maintain CPP 60–70 mmHg with vasopressors (noradrenaline preferred)
         ↓ ICP still >20 mmHg

TIER 2
  - Neuromuscular blockade (cisatracurium)
  - Mild hyperventilation (PaCO2 30–35 mmHg) — short-term only
  - CT scan to rule out new surgical lesion
  - Barbiturate coma (thiopentone/pentobarbital) — titrate to burst suppression
         ↓ ICP still refractory

TIER 3 (Salvage)
  - Decompressive craniectomy (bifrontal or hemicraniectomy)
  - Hypothermia (32–34°C) — controversial; only if other tiers failed

---

Specific Therapies

Osmotherapy

Hyperventilation

• Mechanism: ↓ PaCO2 → cerebral vasoconstriction → ↓ CBF → ↓ ICP
• Only for acute herniation (blown pupil, Cushing's triad) as a bridge to definitive treatment
• Target: PaCO2 30–35 mmHg (short-term); avoid <25 mmHg (profound cerebral ischaemia)
• Prophylactic hyperventilation is contraindicated in TBI

Decompressive Craniectomy

• RESCUEicp trial (NEJM 2016): Decompressive craniectomy reduced mortality but increased rate of vegetative state/severe disability; survival benefit shown
• DECRA trial: Early bifrontal DC for diffuse injury → more unfavourable outcomes; controversial
• Current consensus: Reserved for refractory ICP after Tier 1-2 measures

Steroids

• CRASH trial (Lancet 2004): Methylprednisolone in TBI → significantly ↑ mortality at 2 weeks and 6 months
• Corticosteroids are CONTRAINDICATED in TBI (BTF Level I recommendation)

---

Anaesthetic Concerns in TBI

Pre-induction

• Assume full stomach → RSI
• Haemodynamic optimisation before induction: Replace blood loss; target MAP ≥80 mmHg BEFORE induction
• Arterial line BEFORE induction in severe TBI
• Avoid pre-oxygenation with high FiO2 for extended periods if concern for aspiration; 3-min breathing at tidal volume OR 8 deep breaths
• C-spine immobilisation throughout

Induction of Anaesthesia

Intubation

• RSI with manual in-line axial stabilisation (MIAS) of C-spine
• Succinylcholine 1.5 mg/kg - rapid onset; does NOT significantly ↑ ICP when preceded by pre-oxygenation and a defasciculating dose is no longer routinely required
• Rocuronium 1.2 mg/kg (with sugammadex available) - alternative if succinylcholine contraindicated
• Avoid coughing, gagging, bucking → all transiently ↑ ICP
• Lidocaine 1.5 mg/kg IV pre-intubation: may attenuate intubation-related ICP spike (evidence limited)
• Use video laryngoscopy for potentially difficult airway while maintaining MIAS

Maintenance

• Ventilation target: PaCO2 35–40 mmHg (normocapnia); SpO2 ≥98%
• Volatile agents: Use ≤1 MAC (higher doses → cerebral vasodilation → ↑ CBF → ↑ ICP); isoflurane and sevoflurane preferred; avoid N2O (↑ ICP and CMRO2)
• TIVA (propofol + remifentanil): Ideal - ↓ CMRO2, ↓ CBF, no direct cerebral vasodilation
• Position: 15-30° head up, neutral neck
• Avoid hypovolaemia: Maintain euvolaemia with isotonic crystalloids (NS 0.9%); avoid hypotonic solutions (worsen cerebral oedema)
• Glucose: Target 6–10 mmol/L; hyperglycaemia worsens neurological outcome
• Temperature: Maintain normothermia; active warming/cooling

Intraoperative ICP Crisis

• Deepen anaesthesia
• Ensure normoventilation (check EtCO2)
• Mannitol 0.5–1 g/kg or HTS bolus
• Ensure adequate MAP/CPP (vasopressors)
• Short-term hyperventilation to PaCO2 30–35 mmHg
• Inform surgeon; consider EVD placement

---

Update in TBI Management (2023-2025)

1. Progesterone for TBI: ProTECT III and SyNAPSe trials — no benefit; ABANDONED
2. Targeted temperature management (TTM): EUROTHERM3235 trial — hypothermia (35°C) for raised ICP → worsened outcomes; routine hypothermia NOT recommended; normothermia is the target
3. Tranexamic acid (TXA): CRASH-3 trial (Lancet 2019) — TXA within 3 hours of injury reduces head injury death if GCS >3 and no major extracranial bleeding
4. Hypertonic saline vs. mannitol: Mounting evidence favouring HTS in haemodynamically unstable TBI
5. Decompressive craniectomy: RESCUEicp — survival benefit; quality of life at 12 months better than expected
6. Ketamine re-evaluated: Meta-analyses confirm no increase in ICP; NMDA antagonism potentially neuroprotective
7. BTF 5th edition (anticipated 2024-2025): Will incorporate these updates

---

Key Points for MD Exam — Q185/186

1. TBI: Mild (GCS 13-15), Moderate (9-12), Severe (3-8); intubate GCS ≤8
2. Secondary injury is the therapeutic target — hypotension (SBP <90) and hypoxia are the most important preventable secondary insults
3. ICP target <20 mmHg; CPP 60-70 mmHg; use tiered approach
4. Corticosteroids are CONTRAINDICATED (CRASH trial) — Level I BTF recommendation
5. RSI with MIAS for intubation; propofol preferred induction agent but beware hypotension
6. Normoventilation (PaCO2 35-40); hyperventilation only for acute herniation as bridge
7. HTS and mannitol: both effective for osmotherapy; HTS preferred in haemodynamic instability
8. CRASH-3: TXA within 3 hours reduces head injury mortality
9. Avoid N2O in TBI; TIVA (propofol/remifentanil) is ideal maintenance
10. Temperature: normothermia; hypothermia is NOT routinely beneficial (EUROTHERM trial)

---

---

Q187–Q192: Brain Death — Diagnostic Criteria, Prerequisites, Tests, and Documentation

---

Definition

"Brain death is the irreversible loss of the capacity for consciousness combined with the irreversible loss of all brainstem functions, including the capacity to breathe." — American Academy of Neurology (AAN) / Neurology 2023 [PMID: 37821233]

Historical Context

• Harvard Ad Hoc Committee, 1968: First proposed criteria for "irreversible coma" as brain death
• Uniform Determination of Death Act (UDDA), USA, 1981: Legal framework
• AAN Practice Parameters: 1995, 2010, 2023 Consensus Guideline (most current)

Classification of Death by Neurological Criteria

---

Causes of Brain Death

Primary Neurological Causes

• Traumatic brain injury (most common) — severe TBI, gunshot wounds
• Subarachnoid haemorrhage (ruptured intracranial aneurysm)
• Intracerebral haemorrhage (hypertensive bleed, AVM rupture)
• Ischaemic stroke (large MCA infarction with massive oedema)
• Hypoxic-ischaemic encephalopathy (post-cardiac arrest, near-drowning, hanging)
• Meningitis / Encephalitis (bacterial, viral, autoimmune)
• Fulminant hepatic failure (cerebral oedema)

Mechanism

• Any cause → ↑ ICP → when ICP ≥ MAP → cessation of cerebral perfusion → complete global cerebral ischaemia → irreversible neuronal death

---

Prerequisites (Must ALL Be Met Before Testing)

Prerequisite 1: Establish Proximate Cause

• An irreversible and identifiable structural or metabolic cause of brain injury must be established
• Neuroimaging (CT/MRI) should be consistent with the diagnosis
• If cause is unknown, ancillary testing is recommended before declaration

Prerequisite 2: Exclude Reversible Causes (Confounders)

Drugs are the single most important confounder. Always obtain a drug screen and calculate adequate washout time. Barbiturate coma: wait until levels are undetectable.

Prerequisite 3: Observation Period

• Adults: No mandatory observation period after cause is established (AAN 2023); many institutions maintain 6-12 hours
• Children (2 months–1 year): 24 hours observation
• Children (1–18 years): 12 hours observation
• Neonates (<37 weeks): Not applicable (criteria not well-established)

Prerequisite 4: Coma — No Response

• Patient must be in complete unresponsiveness/coma
• GCS = 3 (no eye opening, verbal, or motor response to stimulation)
• Eyes closed; no purposeful movements

---

The Three Components of Brain Death Testing

BRAIN DEATH DECLARATION
         │
    ┌────┴────┐
    │         │         │
COMA     ABSENCE OF    APNOEA
(No       ALL BRAINSTEM  TEST
response)   REFLEXES    POSITIVE

---

Component 1: Establish Coma (No Cortical Responsiveness)

• No eye opening, verbal response, or motor response to stimulation
• Noxious stimuli: Supraorbital pressure, nail bed pressure, sternal rub
• Critical: Any purposeful movement (localising, withdrawal to pain) EXCLUDES brain death
• Spinal cord reflexes may persist (e.g., triple flexion, Lazarus sign) → do NOT exclude brain death (spinal cord can function without brain)

---

Component 2: Absence of All Brainstem Reflexes

Brainstem Reflexes Tested (Cranial Nerve Function)

All 6 brainstem reflexes must be absent for brain death declaration

---

Component 3: The Apnoea Test — The Most Critical Test

Rationale

• The medullary respiratory centres control spontaneous breathing
• In brain death, these centres are irreversibly destroyed
• Even maximal CO2 stimulus (PaCO2 ≥60 mmHg) should fail to trigger spontaneous breathing

Prerequisites Before Apnoea Testing

• Core temperature ≥36.5°C
• SBP ≥100 mmHg (haemodynamic stability)
• PaO2 ≥200 mmHg (pre-oxygenate with 100% O2 for 10 min)
• PaCO2 35-45 mmHg at baseline (normocarbia before test)
• Correct metabolic abnormalities
• No recent sedative drugs

Technique

Step 1: Pre-oxygenate with FiO2 = 1.0 for 10 minutes
        Target: SpO2 = 100%, PaO2 >200 mmHg
        Baseline ABG: PaCO2 35-45 mmHg
                     ↓
Step 2: Disconnect ventilator
        Deliver 100% O2 via tracheal catheter at 6 L/min (apnoeic oxygenation)
        OR maintain CPAP with 100% O2
        Observe for any spontaneous respiratory effort for 8-10 minutes
                     ↓
Step 3: Repeat ABG at 8-10 min
        Target: PaCO2 rise ≥20 mmHg above baseline
        OR PaCO2 ≥60 mmHg (absolute threshold)
                     ↓
                 NO BREATHS?
               /              \
              YES              NO
               ↓                ↓
      Test POSITIVE       Test NEGATIVE
      (Confirms BD)    (Does NOT confirm BD)

Apnoea Test - Positive Result

Positive apnoea test = No spontaneous respiratory effort when PaCO2 ≥60 mmHg (or rises ≥20 mmHg from normal baseline)

Apnoea Test - Abortion Criteria

• SpO2 <85% for >30 seconds
• SBP <90 mmHg
• Cardiac arrhythmia
• Unable to achieve target PaCO2 rise → Return to ventilator; proceed to ancillary/confirmatory testing instead

---

Ancillary / Confirmatory Tests

• Clinical testing cannot be completed (e.g., facial trauma precluding corneal testing, tympanic membrane perforation precluding caloric testing)
• Apnoea test is aborted
• Drug levels uncertain
• Primary infratentorial injury (testing may be unreliable)
• AAN 2023 update: Clarifies specific indications for each ancillary test

---

Number of Physicians and Examinations Required

---

Documentation of Brain Death

Legal and Ethical Requirements

1. It establishes legal time of death
2. Allows withdrawal of life support
3. Is prerequisite for organ donation
4. Protects clinicians from medico-legal challenge

Documentation Checklist

BRAIN DEATH DOCUMENTATION FORM
─────────────────────────────────
1. PATIENT DETAILS
   Name, age, hospital no., ward, date/time

2. DIAGNOSIS LEADING TO BRAIN DEATH
   Cause of brain injury + CT/MRI findings

3. PREREQUISITES CONFIRMED
   □ Core temperature ≥36°C (recorded: ___°C)
   □ SBP ≥100 mmHg (recorded: ___mmHg)
   □ Drug exclusion: Last sedative given ___ ; Time since last dose ___
      Drug levels: ___ (within normal/undetectable)
   □ Metabolic/endocrine causes excluded: Na __, Glucose __, Mg __
   □ No neuromuscular blockade (TOF confirmed: ___)

4. BRAINSTEM REFLEXES (Time of examination: ___)
   □ Pupillary reflex: Right ___ Left ___ (size, fixed/reactive)
   □ Corneal reflex: Right ___ Left ___
   □ Oculo-vestibular (caloric): Right ___ Left ___
   □ Oculo-cephalic: ___
   □ Gag reflex: ___
   □ Cough reflex: ___

5. APNOEA TEST
   □ Pre-test PaCO2: ___ mmHg
   □ Pre-test PaO2: ___ mmHg
   □ Duration of disconnection: ___ min
   □ Post-test PaCO2: ___ mmHg
   □ Spontaneous respiratory efforts: YES / NO
   □ Apnoea test result: POSITIVE / NEGATIVE / ABORTED

6. ANCILLARY TEST (if performed)
   Test type: ___ ; Result: ___

7. SECOND EXAMINATION (if required)
   Time: ___ ; Physician: ___

8. DECLARATION
   Time of brain death: ___
   Date: ___
   Physician 1 (signature, name, qualification): ___
   Physician 2 (signature, name, qualification): ___

9. FAMILY NOTIFICATION (time/name of person notified): ___

10. ORGAN DONATION DISCUSSION: YES / NO
    OPO contacted: YES / NO

---

Brain Death vs. Other States — Differential Diagnosis

---

Organ Donation After Brain Death (DBD)

Anaesthetic Management of the Brain-Dead Donor

• Haemodynamic instability is universal: central DI (diabetes insipidus), neurogenic shock, cardiovascular collapse
• Hormone replacement therapy (HRT): T3/T4 + vasopressin + corticosteroids + insulin
• Targets for organ preservation:
  • SBP 100-120 mmHg; MAP 60-80 mmHg
  • SpO2 ≥98%; PaO2 60-100 mmHg
  • CVP 6-10 cmH2O
  • Hb ≥10 g/dL
  • Urine output 0.5–3 mL/kg/hr
  • Temperature 36-37.5°C
• Despite brain death, NMBDs are still given for surgery (spinal reflexes cause muscle movement)
• Opioids and volatile agents are still used intraoperatively (controversial; spinal-level reflexes; to prevent hypertensive response to surgical stimulation → could reduce organ perfusion)

---

Key Points for MD Exam — Q187-192

1. Brain death = irreversible cessation of all brain functions including brainstem = legal death
2. Three prerequisites: exclude confounders (drugs, hypothermia, metabolic), establish cause, haemodynamic stability
3. Drugs are the most important confounder — must document 5 half-lives have elapsed; check levels
4. Three components: Coma + Absent brainstem reflexes + Positive apnoea test
5. 6 brainstem reflexes must ALL be absent: Pupillary, corneal, oculo-vestibular (caloric), oculo-cephalic, gag, cough
6. Apnoea test positive = no breathing when PaCO2 ≥60 mmHg (or rise ≥20 mmHg from normal baseline)
7. Spinal cord reflexes (triple flexion, Lazarus sign) may persist → do NOT negate brain death
8. Ancillary tests (EEG, 4-vessel cerebral angiography, nuclear scan, TCD) used when clinical exam is incomplete
9. Cerebral angiography = gold standard ancillary test (absent intracranial flow)
10. India (THOA 2011): Panel of 4 doctors; 2 examinations; neither can be part of transplant team
11. AAN 2023 Consensus Guideline [PMID: 37821233]: Most current guidelines; integrates paediatric and adult criteria; 85 recommendations
12. Documentation must include time of death, both examiners' signatures, drug exclusion, all reflex findings, apnoea test result

---

Q193, Q194 & Q195: Posterior Fossa Craniotomy — Anaesthetic Management and Complications

---

Introduction

• Anatomical proximity to vital brainstem centres (cardiovascular, respiratory)
• Multiple possible surgical positions, each with unique complications
• Venous air embolism (VAE) is the signature complication
• Cranial nerve monitoring demands careful anaesthetic choices
• Postoperative complications can be immediately life-threatening

---

Anatomical Considerations

• Cerebellum (co-ordination)
• Brainstem: midbrain, pons, medulla (vital centres - cardiovascular, respiratory, level of consciousness)
• Cranial nerves IV-XII (especially V, VII, VIII, IX, X at CPA)
• Venous sinuses: transverse, sigmoid, superior petrosal
• Fourth ventricle and Sylvian aqueduct (obstruction → obstructive hydrocephalus)

• Dural venous sinuses are non-collapsible → prone to VAE when surgical field is above heart level
• Brainstem manipulation → cardiovascular instability (Cushing's reflex, arrhythmias, sudden hypotension/hypertension)
• Postoperative swelling can cause acute obstructive hydrocephalus and respiratory compromise (IX/X nerve oedema)

---

Preoperative Assessment

History

• Symptoms of raised ICP (headache - worse in morning, vomiting, papilloedema, altered vision)
• Focal neurological deficits: cerebellar signs (ataxia, dysmetria, nystagmus), CN deficits (diplopia, facial weakness, dysphagia, dysphonia)
• Duration and progression of symptoms
• Pre-existing cardiovascular or respiratory disease
• Prior neurosurgery, CSF drainage

Relevant Investigations

• MRI brain with contrast (gold standard): tumour size, location, relation to brainstem, ventricular system, oedema
• CT brain: hydrocephalus, calcification, bony involvement
• CT angiography: vascular tumours (haemangioblastoma, glomus jugulare)
• Audiometry, vestibular tests (acoustic neuroma)
• Echocardiography: mandatory to detect patent foramen ovale (PFO) if sitting position planned (PFO in ~25% of population → risk of paradoxical cerebral air embolism)
• Routine bloods, coagulation (corticosteroid use may affect glucose; anticoagulants)
• Neuromonitoring requirements (SSEP, MEP, facial nerve EMG, BAER, CN monitoring)

Optimisation

• Corticosteroids (dexamethasone 8-16 mg/day): Reduce peritumoral oedema; start 48 hours pre-op
• Antiepileptics (if seizure history)
• Diuretics (if acute raised ICP; emergency EVD if severe hydrocephalus)
• Pre-operative PFO assessment essential if sitting position contemplated

---

Surgical Positions for Posterior Fossa Surgery

---

Anaesthetic Management

Premedication

• Dexamethasone 8 mg IV (if not already started) to reduce oedema
• Avoid benzodiazepines in patients with raised ICP or brainstem compromise (respiratory depression risk)
• Antiemetics (ondansetron 4 mg): Posterior fossa tumours and manipulation → high PONV risk
• Continue regular antiepileptics on the morning of surgery

Monitoring (Standard + Specific)

• ECG, SpO2, NIBP, EtCO2, temperature, urine output
• Intra-arterial blood pressure (radial artery, non-dominant): Beat-to-beat BP; ABG
• Central venous catheter (CVC): Right atrial/CVJ placement for VAE aspiration; mandatory for sitting position
  • Optimal tip position: junction of SVC and right atrium (2 cm below junction) to aspirate air
  • Confirm position with CXR or intracardiac ECG (P-wave biphasic = correct position)
• Precordial Doppler (PCD): Most sensitive non-invasive monitor for VAE; placed over right heart (left parasternal, 3rd-4th intercostal space)
• Transoesophageal Echocardiography (TOE/TEE): Most sensitive overall; detects VAE and paradoxical embolism; used in sitting position if available
• BIS: Depth of anaesthesia
• Neuromonitoring (case-specific):
  • SSEP + MEP: spinal cord function (foramen magnum surgery)
  • BAER: Auditory pathway (acoustic neuroma/CPA surgery)
  • Facial nerve EMG: Continuous monitoring (acoustic neuroma, CPA tumours)
  • CN monitoring (IX, X, XI, XII EMG): Brainstem/lower CN surgery

Induction

Goals

1. Smooth induction without coughing, bucking (↑ ICP)
2. Maintain CPP
3. Avoid hypotension, hypertension, hypercarbia

Agents

• Propofol 1.5-2 mg/kg IV: ↓ CMRO2, ↓ CBF, ↓ ICP; preferred for induction and TIVA
• Fentanyl 2-3 µg/kg (or remifentanil): Blunts laryngoscopy response
• Lignocaine 1.5 mg/kg IV 90 sec before laryngoscopy: Attenuates ICP spike
• Rocuronium 0.6-1 mg/kg (or vecuronium): Avoid succinylcholine if ICP very high
  • If neuromonitoring (MEP) required: Minimum NMBD — use short-acting agents; allow complete recovery before MEP acquisition
• Controlled ventilation: target PaCO2 35-40 mmHg (normoventilation)

Airway

• RAE endotracheal tube (Ring-Adair-Elwyn) or reinforced (armoured) ETT preferred:
  • Less likely to kink with head turning/flexion
  • Oral RAE tube directed away from surgical field
• Secure ETT firmly (head manipulation intraoperatively → displacement risk)
• Head flexion check: After final positioning, ensure 2 finger breadths between chin and sternum (prevents venous obstruction and cervical cord injury)
• Throat pack: Prevents blood accumulation in posterior pharynx

Positioning

Sitting Position — Special Considerations

1. Position the patient slowly to prevent haemodynamic collapse
2. Compression stockings + pneumatic compression devices: prevent lower limb venous pooling
3. Vasopressors (noradrenaline, metaraminol) ready — sitting ↓ venous return → ↓ CO → ↓ MAP
4. Head fixed in Mayfield 3-pin skull clamp
5. Chin-chest distance ≥2 finger breadths (prevents venous obstruction of jugular veins → venous engorgement, and cervical cord ischaemia)
6. Arms on padded arm rests
7. Legs elevated slightly (anti-Trendelenburg effect mitigated)
8. Position CVC tip at SVC-RA junction before positioning

Maintenance

• TIVA preferred (propofol 4-8 mg/kg/hr + remifentanil 0.1-0.3 µg/kg/min):
  • Avoids volatile-induced cerebral vasodilation
  • Essential if neuromonitoring (MEP) is used (volatile agents suppress MEPs)
  • Reduces PONV (remifentanil → low volatiles; propofol antiemetic)
• Low-dose volatile (sevoflurane ≤0.5 MAC + N2 + O2): Alternative if TIVA not available; avoid >1 MAC
• Avoid N2O:
  • Expands air bubbles (VAE risk) — absolutely contraindicated in sitting position
  • Diffuses into pneumocephalus postoperatively → tension pneumocephalus
• Ventilation: Normoventilation (PaCO2 35-40 mmHg); mild hyperventilation ONLY for acute ICP rise
• Fluid management: Isotonic crystalloids (NS 0.9%); avoid glucose-containing solutions; avoid hypotonic solutions; maintain euvolaemia
• MAP target: ≥70 mmHg (vasopressors as needed in sitting position)
• Steroids: Continue dexamethasone intraoperatively

Emergence

• Smooth extubation: Coughing/bucking raises ICP and can disrupt surgical haemostasis → use remifentanil to smooth emergence; consider dexmedetomidine
• Lidocaine 1.5 mg/kg IV at extubation: Suppresses cough reflex
• Deep extubation (controversial in posterior fossa — airway reflexes may be impaired)
• Consider delayed extubation in ICU if:
  • Prolonged surgery, significant oedema
  • Cranial nerve IX/X involvement (dysphagia → aspiration risk)
  • Large tumour resection near brainstem
  • Haemodynamic instability
  • Inadequate swallowing/gag reflex at end of case
• Neurological assessment immediately post-extubation

---

Complications and Management (Q194)

1. Venous Air Embolism (VAE) — The Signature Complication

Mechanism

• Surgical field above heart level → subatmospheric pressure in open venous sinuses/emissary veins/bone edge veins → air entrainment → right heart → pulmonary circulation

Incidence by Position

Monitoring Sensitivity for VAE (Most to Least Sensitive)

1. Transoesophageal echocardiography (TOE) — gold standard (detects 0.02 mL/kg)
2. Precordial Doppler — most sensitive non-invasive; detects 0.05 mL/kg
3. EtCO2 — sudden fall = air emboli obstructing pulmonary circulation
4. Pulmonary artery pressure — sudden rise
5. Oesophageal stethoscope — "mill-wheel" murmur (late sign, large embolism)
6. SpO2 — falls late
7. ECG — ST changes, right heart strain (late)

Flowchart: Management of VAE

Precordial Doppler detects air / EtCO2 suddenly ↓
              ↓
IMMEDIATE ACTIONS (simultaneously):
1. INFORM SURGEON → flood surgical field with saline / pack wound
2. COMPRESS JUGULAR VEINS bilaterally (↑ venous pressure → reduces entrainment)
3. STOP N2O immediately (if being used) → switch to 100% O2
4. LOWER HEAD (if sitting — modified Trendelenburg to equalise venous pressure)
5. ASPIRATE CVC (right atrial catheter) → withdraw air via 20 mL syringe
              ↓
If haemodynamic collapse:
6. VASOPRESSORS (ephedrine, adrenaline)
7. CPR if cardiac arrest
8. Durant's manoeuvre: LEFT LATERAL DECUBITUS position (air floats away from RV outflow tract)
9. Consider hyperbaric O2 if cerebral or coronary air embolism suspected
              ↓
ONCE STABLE:
Surgeon identifies and occludes source of air entry (bone wax, Gelfoam, ligation)
Continue monitoring for recurrence

Paradoxical Air Embolism

• Air passes through patent foramen ovale (PFO) → left heart → systemic circulation → cerebral, coronary, renal embolism
• Incidence if PFO present: ~25%
• Pre-operative echocardiography mandatory
• If PFO found: Sitting position is a relative/absolute contraindication depending on institutional policy; consider alternative position

2. Cardiovascular Instability During Surgery

Brainstem Manipulation

• Handling medulla/brainstem → sudden, profound haemodynamic changes:
  • Hypotension + bradycardia (vagal/IX-X stimulation)
  • Hypertension + tachycardia
  • Cushing's response (severe: hypertension + bradycardia = sign of critical ICP rise)
  • Arrhythmias (nodal rhythm, VT, VF — rare)
• Management: Alert surgeon immediately → stop/reduce surgical manoeuvre → treat arrhythmia; atropine for severe bradycardia; vasopressors for hypotension

Sitting Position Haemodynamics

• ↓ Venous return → ↓ cardiac output → ↓ MAP
• Prevention: Slow positioning; elastic stockings; fluid loading; vasopressors as needed

3. Tension Pneumocephalus

• Air enters intracranial cavity during surgery → postoperatively N2O causes expansion → mass effect
• Prevention: Avoid N2O perioperatively
• Clinical features: Postoperative neurological deterioration, headache, "Mt Fuji sign" on CT
• Treatment: Neurosurgical decompression (needle aspiration via Burr hole) + 100% O2

4. Cranial Nerve Injury

• Monitoring: Continuous facial nerve EMG intraoperatively
• Post-op: Eye care (taping, artificial tears), swallowing assessment before oral feeding

5. Postoperative Airway Compromise

• Bilateral vocal cord paralysis (X nerve injury) → stridor, acute respiratory failure
• Cerebellar/brainstem oedema → ↓ GCS → loss of airway protection
• Management: Elective postoperative ICU with ventilation until swallowing/airway reflexes confirmed

6. Postoperative Cerebellar Oedema and Haemorrhage

• Life-threatening if massive swelling → re-intubation; urgent CT; return to theatre for haematoma evacuation or craniectomy

7. Obstruction of 4th Ventricle / Hydrocephalus

• Postoperative oedema or residual tumour → obstructs CSF flow → acute hydrocephalus
• Management: EVD placement; urgent CT; ventriculoperitoneal shunt if persistent

---

Key Points for MD Exam — Q193-195

1. Sitting position carries highest VAE risk (25-45%) — requires mandatory: precordial Doppler, CVC at SVC-RA junction, TOE, avoid N2O
2. Pre-operative echocardiography is mandatory before sitting position — PFO detected in 25% → contraindication to sitting
3. TIVA is preferred for posterior fossa surgery — avoids volatile vasodilation, mandatory if MEP monitoring
4. Avoid N2O — expands VAE, causes tension pneumocephalus, ↑ PONV
5. VAE management: Flood field + compress jugulae + 100% O2 + aspirate CVC + Durant's manoeuvre (left lateral)
6. Reinforced/armoured or RAE ETT prevents kinking with head positioning
7. CN IX/X injury → delayed extubation — confirm swallowing before removing airway
8. Brainstem manipulation → sudden cardiovascular changes — inform surgeon immediately
9. Head flexion: Minimum 2 finger breadths chin-sternum; prevents jugular compression and cervical cord injury
10. Smooth emergence is critical — coughing raises ICP and disrupts haemostasis

---

---

Q196: Neurosurgical Positions — Types and Intraoperative Complications

---

Introduction

• Positions are often extreme and prolonged
• The surgical field must be optimised for access while protecting the patient
• Each position carries specific risks to the patient distinct from those in other surgical positions
• Position changes during anaesthesia carry added physiological and mechanical dangers

---

Positions Used in Neurosurgery

1. Supine Position

• Anterior cranial fossa (frontal lobe, pituitary, anterior circulation aneurysms)
• Frontotemporal (pterional) craniotomy
• Carotid endarterectomy

• Head may be turned to one side, extended, or elevated (reverse Trendelenburg 15-30° for ↓ ICP)

• Venous obstruction (excessive neck rotation → compresses contralateral IJV)
• Pressure sores (heels, occiput)
• Brachial plexus stretch (arm abduction >90°)
• Endotracheal tube kinking with neck rotation

---

2. Lateral Position (Park Bench / Lateral Decubitus)

• Posterior fossa tumours, acoustic neuroma, CPA lesions
• Microvascular decompression (hemifacial spasm, trigeminal neuralgia)
• Temporal craniotomy
• Vertebral artery surgery

---

3. Sitting Position (Beach Chair / Modified)

• Midline posterior fossa (cerebellar vermis, fourth ventricle)
• Pineal tumours (some)
• Foramen magnum decompression (Chiari malformation)
• High cervical spine

• Excellent midline surgical access
• Lower ICP (gravity aids venous drainage)
• Reduced retraction injury
• Better facial nerve monitoring
• Reduced blood loss (gravity)
• Better operative field visibility

• Confirmed PFO (paradoxical embolism risk) — absolute/relative depending on policy
• Severe haemodynamic instability
• Cervical spine disease limiting flexion

---

4. Prone Position

• Midline posterior fossa and suboccipital craniotomy
• Posterior spinal cord surgery
• Occipital craniotomy
• Tethered cord release

---

5. Concorde / Three-Quarter Prone Position

• CPA tumours
• Vertebral artery surgery
• Foramen magnum

---

Summary: Positions vs. Key Complications

POSITION        VAE RISK    HAEMODYNAMICS    NERVE INJURY RISK
─────────────────────────────────────────────────────────────
Sitting         HIGHEST     BP ↓ (pooling)   Cervical cord, peroneal
Lateral         Moderate    Minimal          Brachial plexus, peroneal
Prone           Lower       ABD compression  Brachial plexus, ocular
Supine          Low         Minimal          Brachial plexus

---

Key Points for MD Exam — Q196

1. Sitting position = highest VAE risk, best surgical access; require precordial Doppler + CVC + avoid N2O; pre-op echo for PFO
2. Prone position = avoid abdominal compression (↑ epidural venous pressure); post-op visual loss from CRAO is rare but devastating
3. Lateral position = axillary roll under CHEST (not axilla) to protect brachial plexus; pad bony prominences
4. All positions: Armoured ETT prevents kinking; confirm tube position after positioning
5. 2-finger rule in any position with neck flexion — prevents venous obstruction and cord injury
6. Neuromonitoring (SSEP) should be recorded immediately after positioning to confirm no positional neurological injury before incision

---

---

Q197 & Q198: Anaesthetic Management of a 3-Year-Old Child with Hydrocephalus for VP Shunt

---

Introduction

• Raised intracranial pressure (ICP) — may be acute or chronic
• Paediatric pharmacology and physiology
• Risk of airway loss from CNS depression
• Anaesthetic agents must not further ↑ ICP

---

Types of Hydrocephalus

---

Preoperative Assessment (Q197)

History

• Duration and progression of symptoms
• Signs of acute raised ICP: Bulging fontanelle, "sunset sign" (eyes deviate downward), altered consciousness, vomiting (effortless, early morning), papilloedema
• Previous VP shunt and failures (revision surgery)
• Neonatal history: prematurity, IVH, meningitis
• Associated anomalies (Chiari, spina bifida, aqueductal stenosis)
• Developmental milestones (assesses chronic ICP effect on cognition)
• Current medications (anticonvulsants, steroids)
• NPO status, recent feed

Examination

• Weight (important for drug dosing)
• Head circumference (compare to centile charts — macrocephaly)
• Fontanelle assessment (anterior fontanelle open until 18 months)
• Neurological status: GCS, pupils, fontanelle tension, eye signs
• Airway assessment: Atlanto-axial instability (Chiari); mouth opening; micrognathia (associated syndromes)
• Cardiovascular, respiratory status

Investigations

• MRI/CT brain: ventricle size, cause of hydrocephalus, degree of cortical mantle thinning
• FBC, electrolytes (hyponatraemia from cerebral salt wasting)
• Coagulation (if acutely ill)
• Blood group and save

Risk Stratification

• Acute hydrocephalus (Grades 1-3): Immediate surgical urgency; may need emergency EVD before definitive shunt
• Chronic hydrocephalus: More elective; optimise preoperatively

---

Anaesthetic Management

Premedication

• Avoid sedative premedication in raised ICP (benzodiazepines → ↓ respiratory drive → ↑ PaCO2 → ↑ ICP)
• EMLA cream over dorsum of hand for IV placement (reduces distress and catecholamine surge)
• Dexamethasone 0.15 mg/kg IV: Reduces peritumoral/periventricular oedema
• Glycopyrrolate 5 µg/kg IM (if bradycardia anticipated — oculovagal reflexes during EVD insertion)

Induction

Key Principle: AVOID ICP SPIKE

• All manoeuvres that cause coughing, straining, crying, hypoventilation must be minimised

Route:

• IV induction preferred in acute raised ICP (more controlled; slower if smooth)
• Gas induction acceptable in children without IV access AND stable ICP — but:
  • Avoid high-dose sevoflurane (>1 MAC) — dose-dependent cerebral vasodilation → ↑ CBF → ↑ ICP
  • Use incremental sevoflurane titration; establish IV access ASAP during inhalational induction

Induction Agents:

• Propofol 2-3 mg/kg IV: ↓ CMRO2, ↓ CBF, ↓ ICP; drug of choice — BUT causes hypotension (use with care, especially if ICP very high)
• Thiopentone 5-7 mg/kg IV: Historical preference; ↓ CMRO2, ↓ ICP; haemodynamic depression
• Ketamine: Previously contraindicated in raised ICP (↑ CBF, ↑ CMRO2, ↑ ICP) — however, current evidence when combined with controlled ventilation shows minimal or no ICP increase; may be used in haemodynamically unstable children — use cautiously
• Avoid etomidate in children <10 years (haemolysis of older formulation; not routinely available)

NMBD:

• Rocuronium 0.6-1 mg/kg (with sugammadex available): Safe, reliable; preferred in paediatrics
• Succinylcholine 2 mg/kg (paediatric dose): Rapid onset for RSI; brief transient ↑ ICP not clinically significant when pre-treated adequately; use if RSI needed and rocuronium/sugammadex not available

Intubation:

• Oral RAE or armoured ETT (head may be repositioned)
• ETT size (uncuffed): Age/4 + 4 mm (or use cuffed for better ventilation control in these patients)
• Cuffed ETTs now preferred in paediatric neuroanesthesia (better ventilation control, less air leak)
• Confirm position (EtCO2 capnography)

Positioning

• Supine with head neutral (slight head-up 15-30° for VP shunt)
• Roll under ipsilateral shoulder to expose neck and abdominal approach
• Head turned contralateral to shunt side
• Careful padding (thin subcutaneous fat → pressure sores develop rapidly in children)
• Eyes taped and protected (no direct pressure)

Maintenance

• TIVA (propofol 3-5 mg/kg/hr + remifentanil 0.1-0.2 µg/kg/min): Preferred — stable ICP, good emergence, minimal PONV
• Alternatively: Low-dose sevoflurane (≤0.5-0.8 MAC in 50% O2/N2 without N2O)
• Avoid N2O: May expand pneumocephalus if dura opened; does not reduce ICP
• Ventilation: Normoventilation (PaCO2 35-38 mmHg in children); avoid hypercarbia
• Fluid: Isotonic crystalloid (0.9% NaCl or PlasmaLyte) 5-10 mL/kg/hr; avoid hypotonic solutions (D5W, 0.45%NS → hyponatraemia → cerebral oedema)
• Maintain normoglycaemia (4-8 mmol/L); avoid glucose-containing fluids unless hypoglycaemia confirmed
• Maintain normothermia (active warming — children cool rapidly)
• Continue neuromuscular block during tunnelling (patient movement disrupts surgical placement)

Intraoperative Concerns

Emergence

• Smooth emergence is essential — straining/coughing ↑ ICP
• Reverse NMBD (glycopyrrolate + neostigmine or sugammadex)
• Lidocaine 1 mg/kg IV at extubation to suppress cough
• Extubate awake (when airway reflexes confirmed — the child must cough/respond to commands)
• Avoid opioids for maintenance (↑ PONV; respiratory depression) — use paracetamol, local infiltration by surgeon
• Antiemetic prophylaxis: Ondansetron 0.1 mg/kg IV; consider dexamethasone (also has cerebral oedema benefit)

Postoperative Care

• Neurosurgical HDU/ICU for at least 24 hours
• Neurological observations every 30 minutes: GCS, pupils, SpO2
• Analgesia: Paracetamol 15 mg/kg PO/IV regularly; codeine (careful in children); local wound infiltration
• Shunt function assessment: Improvement in neurological status; head circumference trend
• Signs of shunt malfunction: Deteriorating GCS, tense fontanelle, "sunset sign" → urgent CT

---

Key Points for MD Exam — Q197/198

1. Avoid sedative premedication in raised ICP children (benzodiazepines → hypoventilation → ↑ ICP)
2. IV induction with propofol preferred in acute raised ICP; use with caution (hypotension = ↓ CPP)
3. Ketamine: No longer absolutely contraindicated in controlled ventilation settings
4. Normoventilation (PaCO2 35-38 mmHg) — avoid both hypercarbia (↑ ICP) and hypocarbia (↓ CBF)
5. Isotonic fluids only — hypotonic solutions cause hyponatraemia and cerebral oedema
6. Avoid N2O; low-dose volatile (≤0.8 MAC) or TIVA
7. Smooth emergence — suppress cough/strain at extubation (lidocaine 1 mg/kg IV)
8. Extubate awake — confirm airway reflexes before extubation
9. Normoglycaemia, normothermia — essential; children prone to hypothermia and glucose instability
10. Postoperative monitoring for shunt malfunction (↓ GCS, tense fontanelle)

---

---

Q199: Awake Craniotomy

---

Introduction and Indications

Indications

• Tumours in eloquent cortex:
  • Low-grade gliomas adjacent to speech/language areas (Broca/Wernicke)
  • Motor cortex tumours
  • Tumours near primary somatosensory cortex
• Epilepsy surgery: Cortical resection near eloquent areas; intraoperative seizure focus mapping
• Deep brain stimulation (DBS): For Parkinson's disease (microelectrode recording requires awake patient)
• AVM resection adjacent to eloquent cortex

Advantages of Awake Craniotomy

• Maximal safe resection: Surgeon can map and identify eloquent cortex in real-time; more aggressive tumour removal than would otherwise be safe
• Better neurological outcomes — lower rates of permanent postoperative neurological deficit
• Faster recovery, shorter hospital stay
• Avoids risks of general anaesthesia

Contraindications

---

Anaesthetic Techniques for Awake Craniotomy

Three Main Techniques

1. ASLEEP - AWAKE - ASLEEP (AAA)
   ─────────────────────────────
   Most common; patient anaesthetised for incision and closure,
   awake during cortical mapping phase
   
2. AWAKE - AWAKE - AWAKE (AAA-full awake)
   ───────────────────────────────────────
   Patient awake throughout; conscious sedation only
   (Monitored Anaesthesia Care - MAC)
   
3. ASLEEP - AWAKE (two-phase)
   ────────────────────────────
   Patient anaesthetised for opening, awake for mapping/resection
   No re-sedation at closure

---

The Asleep-Awake-Asleep Technique

Phase 1: ASLEEP (Induction and Opening)

• LMA (Laryngeal Mask Airway) — preferred over ETT:
  • Easy to remove when patient needs to be woken
  • Less stimulating than ETT → better haemodynamic stability
  • Flexible/reinforced LMA ideal (head fixed in frame with limited access)
  • Cannot use if airway protection is uncertain (regurgitation risk → ETT needed)
• Alternative: ETT (especially if obese, OSA, GERD, concerns about airway); remove before awakening phase

• Propofol TCI (target-controlled infusion): 2-4 µg/mL effect-site target; provides ↓ ICP and smooth induction
• Remifentanil TCI: 2-4 ng/mL; ultra-short acting → easily switched off when awakening patient
• Dexmedetomidine infusion (0.3-0.7 µg/kg/hr): Increasingly used — provides sedation, analgesia, anxiolysis, minimal respiratory depression, cooperative patient when awake; IDEAL agent for awake craniotomy
  • Akavipat et al. J Clin Neurosci 2024 (PMID: 39079421) — systematic review confirms dexmedetomidine provides superior anxiolysis and sedation with less respiratory depression vs. other agents
• Low-dose sevoflurane with LMA: Alternative for Phase 1 if TIVA not preferred
• Avoid high-dose opioids (PONV; respiratory depression)

SCALP INNERVATION and BLOCK POINTS
──────────────────────────────────────────────────────────────
Nerve                    Origin     Block Site
──────────────────────────────────────────────────────────────
Supraorbital (frontal)   CN V1      Superior orbital rim
Supratrochlear           CN V1      Medial forehead
Zygomaticotemporal       CN V2      Lateral orbital rim
Auriculotemporal         CN V3      Anterior to tragus
Lesser occipital         C2         Posterior to SCM
Greater occipital        C2         Medial to occipital protuberance
Greater auricular        C2,C3      Mastoid/ear
──────────────────────────────────────────────────────────────

• Also inject local anaesthetic at pin sites (Mayfield skull clamp) — most painful stimulus

• Dexamethasone 4-8 mg IV (reduces cerebral oedema, anti-emetic)
• Prophylactic antibiotics (cefuroxime 1.5 g IV)
• Mannitol 0.5 g/kg (if brain relaxation needed)

Phase 2: AWAKE (Cortical Mapping)

• Stop propofol/remifentanil (ultra-short acting → patient awakens within minutes)
• Continue low-dose dexmedetomidine (maintains calm, cooperative state without respiratory depression)
• Remove LMA when patient awake and cooperative
• CRITICAL: Patient must be calm, able to respond to commands, and follow simple tasks

• Language mapping (Broca/Wernicke): Patient names objects, counts, reads, follows commands — surgeon delivers bipolar electrical stimulation to cortex; positive mapping = speech arrest/error at that point
• Motor mapping: Continuous voluntary limb movement; any weakness/arrest during stimulation identifies motor cortex
• Sensory mapping: Patient reports any paresthesiae

• Maintain calm environment; reassure patient continuously
• Monitor vital signs (invasive BP)
• Oxygen supplementation via nasal cannula (2-4 L/min)
• Continue dexmedetomidine infusion (or small doses of remifentanil)
• Target BIS 65-85 (cooperative sedation range)
• Be ready to deepen anaesthesia rapidly if:
  • Seizure occurs (intraoperative seizure from cortical stimulation)
  • Patient becomes agitated or unable to cooperate
  • Airway compromise

Phase 3: ASLEEP (Closure — if AAA technique)

• Restart propofol/remifentanil or deepen dexmedetomidine
• Re-insert LMA or continue with face mask ventilation
• Surgical closure proceeds
• Emerge as for standard craniotomy

---

Monitoring for Awake Craniotomy

• Invasive arterial line (radial): Beat-to-beat BP monitoring
• ECG, SpO2, EtCO2 (sidestream capnometry via nasal cannula or face mask)
• Temperature
• BIS (guidance of sedation depth)
• Communication monitoring is itself a form of monitoring — the patient's ability to speak/move is the real-time functional monitor

---

Patient Preparation and Psychological Support

• Detailed explanation of the procedure and expectations
• Practice the intraoperative tasks (naming objects, counting)
• Anxiety assessment; reassurance; address questions
• Build rapport with anaesthesiologist and neuropsychologist
• Avoid anxiolytic premedication (will impair cooperation during awake phase)

---

Key Points for MD Exam — Q199

1. Indication: Tumour/epilepsy surgery near eloquent cortex (language/motor/sensory) requiring intraoperative cortical mapping
2. Most common technique: Asleep-Awake-Asleep (AAA) with LMA and propofol/remifentanil TIVA
3. Dexmedetomidine is the preferred sedation agent for the awake phase — cooperative, calm patient with minimal respiratory depression; confirmed by meta-analysis (PMID: 39079421)
4. Scalp nerve block is mandatory and essential — blocks supraorbital, supratrochlear, auriculotemporal, zygomaticotemporal, greater/lesser occipital, greater auricular nerves
5. LMA preferred over ETT — easy removal; less stimulating
6. Patient cooperation is the functional monitor — patient must perform language/motor tasks during cortical stimulation
7. Intraoperative seizure (3-10%) — managed with cold irrigation, propofol bolus, midazolam; rarely needs full GA
8. Avoid N2O — PONV, pneumocephalus; avoid high-dose opioids — PONV, respiratory depression
9. BIS target 65-85 during awake phase; deeper for asleep phases (40-60)
10. Thorough preoperative psychological preparation is essential for patient cooperation

---

Q563: Newer Modes of Ventilation

---

Introduction

• Better patient-ventilator synchrony
• Reduced ventilator-induced lung injury (VILI)
• Preserving diaphragmatic activity (prevent disuse atrophy)
• Lung-protective strategies (low tidal volume, permissive hypercapnia)
• Minimising sedation requirements

---

Classification of Ventilation Modes

VENTILATION MODES
│
├── FULLY CONTROLLED (No patient effort)
│    ├── Volume Controlled Ventilation (VCV/CMV)
│    ├── Pressure Controlled Ventilation (PCV)
│    └── High Frequency Ventilation (HFV)
│
├── PARTIALLY SUPPORTED (Patient-triggered + machine-supported)
│    ├── Assist-Control Ventilation (ACV)
│    ├── SIMV (Synchronised Intermittent Mandatory Ventilation)
│    ├── Pressure Support Ventilation (PSV)
│    ├── BIPAP (Bilevel Positive Airway Pressure)
│    └── APRV (Airway Pressure Release Ventilation)
│
├── SPONTANEOUS (Patient-driven + machine support)
│    ├── CPAP
│    ├── Pressure Support Ventilation (unsupported spontaneous)
│    └── NIPPV (Non-Invasive Positive Pressure Ventilation)
│
└── NOVEL/INTELLIGENT MODES
     ├── Proportional Assist Ventilation (PAV)
     ├── Neurally Adjusted Ventilatory Assist (NAVA)
     ├── Adaptive Support Ventilation (ASV)
     ├── Mandatory Minute Ventilation (MMV)
     └── High Flow Nasal Oxygen (HFNO/HFOT/THRIVE)

---

Newer/Advanced Modes in Detail

1. Proportional Assist Ventilation (PAV)

• Principle: Ventilator delivers pressure proportional to the patient's own inspiratory effort (both flow-proportional and volume-proportional support)
• Patient controls rate, depth, and duration of each breath
• Ventilator amplifies patient effort by a set gain factor
• Advantages: Better patient-ventilator synchrony; reduced work of breathing; less over-assist
• Limitations: Requires intact respiratory drive; runaway phenomenon if leak present

2. Neurally Adjusted Ventilatory Assist (NAVA)

• Principle: Electrical activity of the diaphragm (Edi) is detected via a special oesophageal catheter → triggers ventilator support proportional to Edi signal
• The most physiological mode — support is truly proportional to neural respiratory drive
• Advantages: Eliminates patient-ventilator dyssynchrony; reduces over-sedation; useful in weaning
• Applications: ARDS, paediatric ICU, difficult weaning patients

3. Adaptive Support Ventilation (ASV)

• Principle: Closed-loop ventilation that automatically adjusts rate and tidal volume to achieve a set minute ventilation while minimising work of breathing and respecting lung-protection targets
• Uses the Otis equation (optimal frequency for minimal work of breathing) to select respiratory rate
• Advantages: Automatic weaning; reduced clinician workload; minimises VILI

4. Mandatory Minute Ventilation (MMV)

• Ensures a preset minimum minute volume is always delivered
• If patient breathes adequately spontaneously → ventilator provides no mandatory breaths
• If patient effort is insufficient → ventilator adds mandatory breaths to meet the target MV
• Advantage: Protects against hypoventilation; allows spontaneous breathing

5. Volume-Assured Pressure Support (VAPS) / Average Volume-Assured Pressure Support (AVAPS)

• Hybrid mode: Combines pressure support (patient comfort) with volume guarantee (safety)
• Used in NIV and home ventilators (Bi-PAP S/T with AVAPS)
• Useful in obesity hypoventilation syndrome, neuromuscular disease

6. Tube Compensation (TC)

• Automatically compensates for the resistance of the endotracheal tube using a calculated pressure boost
• Reduces imposed work of breathing from ETT

---

Summary Table: Newer Modes

---

Q564: Assist-Control Ventilation (ACV)

---

Definition

---

How It Works

PATIENT TRIGGERS BREATH?
         ├── YES → Ventilator ASSISTS → delivers full preset VT or P (ASSIST mode)
         └── NO (within set backup rate period) → Ventilator CONTROLS → delivers preset VT or P (CONTROL mode)

RESULT: Every breath, regardless of origin, gets full ventilator support

• Set parameters: Tidal volume (VCV-ACV) or inspiratory pressure (PCV-ACV), respiratory rate (backup), FiO2, PEEP, inspiratory time
• Patient can breathe above the backup rate — each patient-triggered breath gets full support
• Patient can NEVER receive less than the set backup rate

---

Variants

---

Advantages of ACV

1. Full ventilatory support — every breath is supported; minimal patient work
2. Rest for fatigued respiratory muscles (acute respiratory failure)
3. Guaranteed minimum minute ventilation even if patient becomes apnoeic
4. Simple to set up and understand
5. Used in the initial management of ARDS, ALI, post-operative patients

---

Disadvantages of ACV

---

Clinical Application

• Post-operative intubated patients: Safe, controlled ventilation during emergence
• Acute severe respiratory failure: ARDS initial phase (with lung-protective settings: VT 6 mL/kg IBW, plateau pressure <30 cmH2O)
• Apnoeic patients (drug overdose, brainstem injury): Controlled ventilation
• Weaning: ACV is NOT ideal for weaning (provides full support every breath); switch to PSV or SIMV for weaning

---

ACV vs. SIMV (Key Comparison)

---

Q565: Inverse Ratio Ventilation (IRV)

---

Definition

---

Rationale and Mechanism

Normal Ventilation (I:E = 1:2)

• Short inspiration → quick pressure build-up
• Long expiration → adequate lung emptying
• Some alveoli may collapse at end of expiration

IRV Mechanism

• Prolonged inspiration → allows gas to enter slow-filling (non-compliant) alveoli with long time constants
• Short expiration → before complete exhalation → generates intrinsic PEEP (auto-PEEP) = air trapping
• Auto-PEEP keeps alveoli open throughout the respiratory cycle → alveolar recruitment
• Decelerating inspiratory flow waveform in PC-IRV → redistributes gas more evenly

---

Types of IRV

---

Effects of IRV

---

Indications

• ARDS / ALI with refractory hypoxaemia despite conventional ventilation and PEEP
• When conventional I:E ratio and PEEP fail to achieve adequate oxygenation
• Neonatal respiratory distress syndrome (NRDS) — used as alternative to HFOV

---

Contraindications

• COPD / Bronchospasm: Auto-PEEP → dangerous hyperinflation → tension pneumothorax
• Raised ICP (↑ intrathoracic pressure → ↓ venous return → ↑ ICP)
• Haemodynamic instability (↓ cardiac output)

---

Disadvantages

1. Requires deep sedation + NMJ blockade — inverse ratio is extremely uncomfortable for conscious patients
2. Auto-PEEP is difficult to quantify — risk of over-distension
3. ↓ Cardiac output due to ↑ mean airway pressure
4. Barotrauma risk
5. Not superior to conventional PEEP strategies in large trials — largely replaced by optimal PEEP titration and APRV in modern practice

---

Q566 & Q567: High-Flow Nasal Oxygen (HFNO) and THRIVE

---

Definition

• The application of HFNO specifically in anaesthesia for peri-intubation preoxygenation and apnoeic oxygenation
• Described by Gustafsson et al. (2017) and popularised as the THRIVE technique

---

Equipment

• Blender: Precisely mixes O2 and air from 21% to 100% FiO2
• Active humidifier: Heats gas to 37°C at 100% relative humidity (37°C, 44 mg/L)
• Heated circuit (prevents condensation)
• Wide-bore soft nasal cannulae (Optiflow, Airvo 2, Precision Flow)

---

Physiological Mechanisms of HFNO

---

THRIVE: Apnoeic Oxygenation in Anaesthesia

Mechanism of Apnoeic Oxygenation

• O2 is absorbed from alveoli → blood at 250 mL/min (basal O2 consumption)
• CO2 enters alveoli from blood at only 8-10 mL/min (far less than O2 absorbed)
• Net result: Alveolar pressure falls → creates a pressure gradient → gas flows down the trachea
• HFNO provides a continuous stream of O2 into the nasopharynx → O2 washes down via this bulk flow
• Result: Oxygenation is maintained far longer than without HFNO during apnoea

PaCO2 Rise During Apnoea

• CO2 rises at ~0.5 mmHg/min normally during apnoea
• THRIVE slows this by flushing CO2 from upper airway dead space but does not eliminate CO2 rise
• Eventually PaCO2 will rise (permissive hypercapnia occurs)

Key Trial: Patel et al. (Anaesthesia, 2015)

• HFNO at 70 L/min in apnoeic patients maintained SpO2 ≥90% for a median of 17 minutes vs. standard pre-oxygenation (3 min)
• Demonstrated safety of THRIVE for prolonged apnoea

---

Clinical Applications of HFNO/THRIVE

1. Perioperative Anaesthesia

2. ICU / Acute Respiratory Failure

• Hypoxaemic respiratory failure (CAP, ARDS, post-extubation)
• Post-extubation respiratory failure — HFNO superior to standard O2; non-inferior to NIV for selected patients
• COVID-19 hypoxaemia — widely used in pandemic; avoids intubation in many patients
• Immunocompromised patients with pneumonia (avoids intubation → reduces mortality)

3. Procedural Sedation

• Maintains oxygenation during upper GI endoscopy, bronchoscopy, ERCP under deep sedation

---

HFNO vs. Conventional Oxygen vs. NIV

---

Contraindications / Limitations of HFNO

• Complete upper airway obstruction
• Apnoea requiring ventilatory support (use NIV/intubation)
• Severe hypercapnic respiratory failure (NIV preferred — HFNO provides minimal CO2 clearance)
• High flow may dry secretions if humidification fails

---

Key Points for MD Exam — Q566/567

1. HFNO: Heated, humidified O2/air blend up to 60-70 L/min via wide-bore nasal cannulae
2. Key mechanisms: Dead space washout, CPAP effect (+3-5 cmH2O), ↑ FiO2, humidification, ↓ work of breathing
3. THRIVE = HFNO applied to apnoeic oxygenation during anaesthesia — extends safe apnoea time to median 17 minutes
4. CO2 still rises during apnoea with THRIVE (~0.5 mmHg/min) — not a ventilation technique
5. Applications: Pre-oxygenation, RSI, difficult airway, laryngeal surgery, post-extubation
6. THRIVE in neuroanesthesia — reviewed by Vaithialingam & Sriganesh 2023 [PMID: 38269192]

---

Q568: Non-Invasive Positive Pressure Ventilation (NIPPV)

---

Definition

• CPAP (Continuous Positive Airway Pressure)
• BiPAP/BIPAP (Bilevel Positive Airway Pressure)
• PSV via mask (Pressure Support Ventilation non-invasively)

---

Physiological Effects of NIPPV

---

Types

1. CPAP (see Q569)

2. BiPAP (Bilevel PAP)

• IPAP (Inspiratory Positive Airway Pressure): Higher pressure during inspiration → assists breath; reduces inspiratory work; aids CO2 elimination
• EPAP (Expiratory Positive Airway Pressure): Lower pressure during expiration = PEEP → prevents alveolar collapse; recruits alveoli
• ΔP = IPAP - EPAP = pressure support = driving force for tidal volume
• Typical settings: IPAP 10-20 cmH2O; EPAP 5-10 cmH2O

---

Indications for NIPPV

---

Contraindications to NIPPV

---

Failure of NIPPV — Indications to Intubate

• Persisting/worsening hypoxaemia (SpO2 <90% on FiO2 >0.5)
• Worsening hypercapnia or acidosis (pH <7.25)
• Inability to maintain airway protection/secretion clearance
• Haemodynamic deterioration
• Loss of consciousness
• Increasing respiratory distress despite NIV

---

Interface Options

• Full face mask: Most common; better seal; more claustrophobia
• Nasal mask: Better tolerated; less effective in mouth-breathers
• Helmet: Full head enclosure; very good seal; used in ARDS; no facial pressure sores; can be uncomfortable

---

Q569: Continuous Positive Airway Pressure (CPAP)

---

Definition

CPAP ≠ PEEP: PEEP is applied during mechanical ventilation (adds to ventilator-delivered breaths); CPAP is applied to spontaneously breathing patients and is itself the pressure level maintained.

---

Mechanism of Action

Spontaneous Breath
         ↓
Patient inhales → CPAP valve maintains set pressure
         ↓
Patient exhales → CPAP valve prevents pressure from falling below set level
         ↓
ALVEOLAR PRESSURE NEVER FALLS BELOW CPAP LEVEL
         ↓
EFFECTS:
1. ↑ FRC (functional residual capacity) → prevents alveolar collapse
2. Alveolar recruitment → ↑ V/Q matching → ↑ PaO2
3. Splints upper airway (OSA mechanism)
4. ↓ Preload/afterload → beneficial in cardiogenic pulmonary oedema
5. ↓ Work of breathing (counteracts auto-PEEP in COPD)

---

Settings

• CPAP level: Typically 5-10 cmH2O (titrated to SpO2 and work of breathing)
• FiO2: 0.21-1.0 (adjusted to maintain SpO2 ≥94%)
• Delivered via: CPAP mask (face mask/nasal), CPAP machine, or anaesthesia machine

---

Clinical Applications

---

CPAP vs. BiPAP

---

Q570: Airway Pressure Release Ventilation (APRV)

---

Definition

Often described as: "CPAP with a safety valve" or "Time-cycled, pressure-controlled ventilation with spontaneous breathing at high lung volume"

---

Settings and Nomenclature

---

Mechanism

HIGH CPAP (P-high) maintained for T-high (4-6 sec)
│
├── Lungs stay inflated at high volume → OPEN LUNG STRATEGY
├── Alveolar recruitment → ↑ FRC → ↑ oxygenation
└── Patient can breathe spontaneously throughout at P-high
         ↓
Brief RELEASE to P-low (0 cmH2O) for T-low (0.2-0.8 sec)
│
├── Lungs deflate partially → CO2 is expelled
├── T-low is cut short BEFORE complete deflation (based on expiratory flow)
│   → End-expiratory flow should be 50-75% of peak expiratory flow
│   → This "catches" the lung before collapse → Intrinsic PEEP generated
└── Return to P-high

---

TCAV (Time-Controlled Adaptive Ventilation)

• Individualised APRV where T-low is adjusted based on patient's expiratory time constant
• Reviewed by Al-Khalisy et al. (Resp Res 2024 [PMID: 38238778])

---

Physiological Benefits

---

Indications

• ARDS / ALI with severe hypoxaemia — particularly early/moderate ARDS
• Patients failing conventional lung-protective ventilation
• Post-traumatic respiratory failure (popular in trauma ICU — "Trauma APRV")
• Prevention of ARDS after high-risk surgery

---

Contraindications

• Obstructive lung disease (COPD, asthma): T-low will auto-PEEP dangerously → hyperinflation
• COPD: Auto-PEEP from short T-low → extremely dangerous
• Brainstem injury (spontaneous breathing may be unreliable)

---

APRV vs. Conventional Low-Tidal-Volume Ventilation (ARDSNet)

---

Q571: High-Frequency Oscillatory Ventilation (HFOT / HFOV)

---

Definition

---

Settings

---

Mechanisms of Gas Exchange in HFOV

1. Direct bulk flow (convective) to alveoli closest to airway
2. Asymmetric velocity profiles (inspiratory vs. expiratory flow profiles differ)
3. Pendelluft (gas redistribution between alveoli with different time constants)
4. Taylor dispersion (axial mixing enhanced by oscillations)
5. Molecular diffusion (CO2 is cleared primarily by this mechanism)

---

Oxygenation and Ventilation Control in HFOV

---

Advantages of HFOV

1. Ultra-lung-protective: VT <1-3 mL/kg (< dead space) → minimal volutrauma
2. Constant MAP → sustained alveolar recruitment → ↑ oxygenation
3. Prevents repetitive alveolar opening/closing (atelectrauma)
4. Useful when conventional ventilation has failed

---

Evidence: HFOV in ARDS

• OSCAR trial (Young et al., NEJM 2013): No significant difference in mortality vs. conventional ventilation in ARDS
• OSCILLATE trial (Ferguson et al., NEJM 2013): HFOV associated with increased mortality vs. lung-protective conventional ventilation in moderate-severe ARDS
• Current recommendation: HFOV is NOT recommended as first-line treatment for adult ARDS (downgraded based on these trials); still used in paediatrics and refractory neonatal cases

---

Clinical Use

---

Q572: High-Frequency Jet Ventilation (HFJV)

---

Definition

---

Equipment

• Jet injector/nozzle: Small-bore cannula or lumen in ETT (Sanders injector, Manujet, Monsoon ventilator)
• Jet source: High-pressure O2 source (300-400 kPa / ~60 psi)
• Entrainment: Bernoulli/Venturi effect entrains room air/gas mixture alongside jet → augments tidal volume
• Delivery sites:
  • Supraglottic (above vocal cords) — percutaneous transtracheal or rigid laryngoscope port
  • Subglottic (below vocal cords) — via ETT jet lumen or transtracheal catheter
  • Endobronchial (for one-lung ventilation in rare cases)

---

Modes

---

Physiological Mechanisms (Similar to HFOV)

1. Bulk flow (convective) to proximal alveoli
2. Asymmetric velocity profiles in conducting airways
3. Pendelluft (gas redistribution between lung units)
4. Taylor (augmented) dispersion — enhanced axial mixing
5. Molecular diffusion — dominant for CO2 clearance

---

Clinical Applications of HFJV

1. Laryngeal and Airway Surgery (Primary Anaesthetic Indication)

• Microlaryngoscopy (suspension laryngoscopy): HFJV via subglottic jet catheter or supraglottic Sanders injector
  • Provides excellent immobile, unobstructed surgical field
  • No endotracheal tube in the way
  • Surgeon has complete access to larynx
• Laser airway surgery: Eliminates flammable ETT from surgical field
• Tracheal/subglottic stenosis dilation
• Laryngotracheal reconstruction
• Tracheostomy under ventilation
• Rigid bronchoscopy (may be used alongside ventilating bronchoscope)

2. Respiratory Failure / ARDS (ICU)

• Rescue mode when conventional ventilation fails
• Particularly for bronchopleural fistula (HFJV reduces airway pressure → ↓ flow through fistula → allows healing)

3. Cardiac Surgery and Interventional Procedures

• Catheter ablation of AF: HFJV eliminates respiratory motion → allows ablation catheter stability
• HFJV reduces diaphragmatic motion → more accurate targeting

4. Percutaneous Procedures

• Renal/liver biopsy, RFA, cryoablation → HFJV stops diaphragm movement

5. Emergency Transtracheal Ventilation

• "Can't Intubate, Can't Oxygenate" (CICO): Percutaneous transtracheal jet ventilation (PTJV) as bridge to surgical airway
• Cannula through cricothyroid membrane → jet ventilator attached → buys time

---

Advantages of HFJV

---

Disadvantages and Complications

---

HFJV vs. HFOV Summary

---

Key Points for MD Exam — Q563-572

1. ACV: Full support every breath — ideal for acute RF; causes diaphragm atrophy and auto-PEEP; not for weaning
2. IRV: I:E >1:1; generates auto-PEEP → recruits alveoli; needs deep sedation + NMBD; largely replaced by APRV
3. HFNO/THRIVE: Heated humidified O2 up to 60-70 L/min; dead space washout + CPAP effect (+3-5 cmH2O); extends safe apnoea to ~17 min (THRIVE); CO2 still rises
4. NIPPV: Non-invasive mask ventilation; best evidence in cardiogenic pulmonary oedema and COPD
5. CPAP: Single constant pressure in spontaneous breathing; ↑ FRC; gold standard for OSA; benefits cardiogenic pulmonary oedema
6. APRV: High CPAP (P-high) + brief T-low release; open lung; preserves spontaneous breathing; less sedation; no Level I RCT mortality data
7. HFOV: Oscillations around MAP; ultra-low VT; OSCAR and OSCILLATE trials → NOT recommended first-line in adult ARDS; still used in neonates/paediatrics
8. HFJV: Short gas jets via nozzle; primary use in laryngeal/airway surgery (no ETT = clear surgical field); also bronchopleural fistula and cardiac ablation; fire risk with laser requires FiO2 <40%
9. THRIVE reviewed in neuroanesthesia by Vaithialingam & Sriganesh 2023 [PMID: 38269192]
10. APRV for lung protection reviewed by Camporota et al. Curr Opin Crit Care 2024 [PMID: 38085878]